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Abstract 
Complex multilayer microfluidics have generated a lot of interest in recent years. Early research 
introduced elastomer microvalves and postulated they would bring about a revolution for 
microfluidic systems, similar in scale to introduction of the transistor for electronic systems. In the 
following years, many researchers have been active in the use of complex multilayer microfluidic 
systems, with numerous high impact research outcomes using these systems as precise and active 
control components, providing fluidic isolation, switching or fluidic actuation, and allowing 
unprecedented sophistication and precise control and automation of experimental conditions. 
While application of complex multilayer microfluidic platforms has been demonstrated in 
numerous research settings, there is little evidence that the technology has become ubiquitously 
accepted, with a lack of evidence for point-of-care application, or widespread acceptance within 
the research community. While the advantages that the technology offers have been well 
documented, the field seems to have failed to gain traction, or facilitate the revolution that was 
predicted on its introduction. 
There are various possible explanations for this lack of acceptance, as with any technology, there 
are caveats to the application of complex multilayer microfluidic systems, however given the broad 
range of demonstrated applications, it is unlikely that the bottleneck in their application is related 
to a fundamental application related limitation. In contrast, fabrication technology utilised in 
realisation of complex multilayer microfluidic systems, has not advanced at the same rate to the 
multitude of application-based publications in the past decade. 
This thesis explores the hypothesis that one of the fundamental limiting factors in widespread 
application of complex multilayer microfluidic systems, is related to the challenges associated with 
fabrication of these systems. To explore this hypothesis, firstly, a new fabrication approach is 
introduced which aims to eliminate many of the challenges associated with traditional multilayer 
fabrication methods, this technique is demonstrated in a proof of concept capacity, fabricating 
common multilayer microfluidic structures and doing so with surprising ease.  
Having developed method with simpler fabrication, it is possible to explore whether overcoming 
the multilayer fabrication bottleneck would allow the advantages inherent to complex multilayer 
microfluidic systems to be applied to fields which would otherwise be considered prohibitively 
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difficult, if reliant on traditional fabrication methods. This hypothesis is investigated through 
harnessing the new, simplified fabrication technique to advance point-of-care photonic biosensor 
research through short term collaborative engagements.  It is found that the use of modular 
building blocks and the simple, rapid fabrication enables sophisticated microfluidic chip prototypes 
to be developed in a very short period of time achieving multiple iterations over a matter of weeks 
and even facilitating collaboration on these integrated platforms remotely. The outcomes of these 
short-term collaborations have produced publications automating the fluid handling of highly 
sensitive interferometric waveguide biosensors and environmental control for a single cell analysis 
platform utilising integrated plasmonic biosensors.        
Having demonstrated that simplifying complex microfluidic fabrication can accelerate the 
development and deployment of these systems to enhance research platforms, the next step was 
to explore whether this simplified system could also lower the barrier to deployment in a clinical 
setting. The ability for the fluidic system to handle whole blood was chosen as a deliberately 
challenging target with great sensitivity to fluid dynamics and large variability in patient samples 
and environmental factors, requiring large number of replicate devices to determine statistical 
significance. Here the fabrication technique is applied to enable a study investigating the 
hemocompatibility of common multilayer control components, paving the way for point of care 
blood handling devices.  It is shown that not only can the technique be used to rapidly develop 
platforms that can be used with blood, but the same technique can produce even hundreds of 
replicates required for limited clinical trials, leading the collaborating clinicians to seriously 
consider these complex microfluidics for future point of care diagnostics.  
In Summary, it has been demonstrated that access to complex multilayer microfluidic systems 
without the fabrication overheads generally associated with these systems can allow their 
application to areas that would otherwise be prohibitively difficult. The fabrication method 
presented can allow rapid development, and rapid and reliable deployment to various research 
applications, while allowing the consistency and throughput required enabling large volume 
fabrication required for clinical investigations.  The fact that such a large advancement toward real 
world application within the scope of a single PhD is possible, supports the hypothesis that 
lowering the barrier to fabricating complex microfluidic devices has the potential to significantly 
increase their scope of application. 
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CHAPTER 1: Introduction 
 
As a facilitating multidisciplinary technology, the field of microfluidics generates impact across a 
broad range of fields [1-3] with diverse applications ranging from micro-propulsion systems for 
spacecraft [4], chemical synthesis [5] environmental monitoring [6] and food safety applications 
[7]. Perhaps most notably, microfluidic technologies have had significant impact within the 
biomedical field in recent years [8]. While complex multilayer microfluidic systems have been 
evident in the literature for decades [9], the accessibility, low cost, and relative ease of fabrication 
introduced with elastomer based complex multilayer systems, has seen the field flourish [10]. in 
following years, complex multilayer microfluidic lab-on-a-chip applications have achieved 
extraordinary levels of sophistication [11-13]. Microfluidic logic circuitry, developed to mirror the 
functionality offered by digital logic [14-17], has demonstrated the potential for new levels of 
reconfigurable automation for lab on a chip devices. Programmable fluidic processors have been 
coupled with biosensors, working toward point of care diagnostics [18-20], and 3-Dimensional 
multilayer organ-on-a-chip research platforms have been developed reproducing in-vivo 
conditions with unprecedented accuracy [21]. 
Introduction of elastomer microvalves valve nearly two decades ago, brought with it the promise 
of breakthroughs for multilayer microfluidic lab-on-a-chip application. Elastomer microvalve 
enabled systems were heralded as a catalyst to microfluidics, as the integrated circuit was to the 
electronics industry. Enabling more complex and precise automated biochemical systems, the 
potential for nearly arbitrary scalability of on chip complexity, promised a revolution like that seen 
in information processing brought by complex electronic integration [22].  
In following years, multilayer microfluidic systems have advanced and broadened in application, 
with success marked by numerous high impact research outcomes. Some success has been seen 
toward the goal of arbitrarily complex and reconfigurable microfluidic systems[19, 23], however 
these advances have generally not seen translation to point of care application, nor have they 
become a widely accepted mainstay within research applications, despite the numerous 
advantages they offer over simpler systems [11]. 
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It is not immediately apparent why complex multilayer microfluidic systems have not gained more 
traction. One potential factor is the ‘chip-in-a-lab’ conundrum [24], this refers to the problem that 
a large number of on-chip control elements generally require similarly large numbers of external 
control systems, and that the cost and complexity of external support equipment tends to scale 
along with on-chip complexity. Various solutions to this problem have been proposed, including 
reducing the number of necessary control lines using parallelisation [25], simple fluid rout 
multiplexing systems [22], or more complex microfluidic logic based multiplexer solutions [11]. 
While solutions to this problem have been proposed, little evidence suggests their potential has 
been fully realised, with a lack of development toward widespread acceptance or point of care 
application within complex multilayer microfluidic systems.  
Other potential issues that may stand in the way of widespread acceptance of complex multilayer 
microfluidic systems could be related to device variability and operational robustness. Alignment 
of multiple thin PDMS layers can pose a significant challenge [26], while bonding of these layers 
can be difficult [27], leading to imperfections or defects, impacting reliability.  Alignment is 
particularly important in the case of encapsulation of components of different materials, as 
commonly used in cell culture systems that make use of integrated commercial membranes [28] 
and it is exactly these complex biological systems that require large numbers of identical and 
reliable replicates.  
Perhaps the most plausible bottleneck for widespread acceptance of complex multilayer 
microfluidic systems, are challenges associated with fabrication of these devices. There are 
numerous examples in the literature of application of these systems, including solutions to some 
of the practical issues inherent to their application, but they are generally limited to high value 
research platforms. The fact that it is difficult to scale existing fabrication methods, makes them 
unsuited to the mass fabrication that would be required for commercial applications, as would be 
required for point of care implementation  
This thesis will explore the hypothesis that one of the fundamental limiting factors in widespread 
application of complex multilayer microfluidic systems, is related to the challenges associated with 
fabrication of these systems.  
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Chapter 2 postulates that it is possible to develop a fabrication method minimising the overheads 
generally associated with fabrication of these devices. This is motivated by the hypothesis of this 
thesis that such a simplified fabrication approach would allow the application of complex 
microfluidics to real world problems, allowing application in areas that would be prohibitively 
difficult to engage when reliant on traditional fabrication methods. This chapter introduces a 
fabrication method that mitigates several major challenges associated with multilayer microfluidic 
fabrication, allowing scaling of on chip complexity without significant impact on fabrication 
complexity. The fabrication method is validated in a proof of concept capacity, through application 
to two common representative fabrication challenges. These applications demonstrate the 
techniques capacity to fabricate a range of different multilayer structures, and handle both simple 
fluids in the form of a droplet generation system, and more complex biological sample fluids, in 
the context of a cell culture platform.  
The level of interest in complex multilayer microfluidic systems over the last decade has resulted 
in a large reservoir of knowledge surrounding multilayer microfluidic components and subsystems. 
Numerous applications of multilayer microfluidic systems have been validated and characterised 
in various settings, with design considerations and detailed performance data available on fluidic 
automation, precise fluid manipulation and environmental control systems.   
Chapter 3 of this thesis investigates the hypothesis that given a simplified fabrication method, it 
should be possible to utilise the reservoir of available literature as plug-and-play adaptable 
modular subsystems. With a sufficiently simplified fabrication method, it should be possible to 
rapidly develop solutions to various real-world problems, with short fabrication turnarounds 
allowing iterative improvements, building on well characterised components that have been 
demonstrated in the literature. In short, it should be possible to engage in short term 
collaborations with end-users unfamiliar with the field, and rapidly develop solutions to their 
research problems through deployment of the numerous advantages inherent to complex 
multilayer microfluidic systems, in a manner not previously practical with traditional fabrication 
methods. As an additional benefit, working with researchers in complementary fields, in 
deployment of this technology, should allow additional insight into other factors that may be 
holding back widespread acceptance of complex multilayer microfluidic systems.  This chapter 
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investigates the practicalities of the fabrication technique outlined in chapter 2, when applied to 
real world photonic biosensor applications, specifically in the context of a point-of-care 
application, and a sophisticated lab on a chip research platform, and was carried out in 
collaboration with researchers in leading groups working with these devices.   
Finally, in chapter 4, the simplified fabrication technique is applied to clinical biological studies 
demanding complex sample fluid handling and requiring large numbers of uniform replicates. 
Manipulation of blood within artificial microsystems is challenging due to its complex and reactive 
nature, generally rendering re-use of devices impractical. Residues from previous samples can 
contaminate subsequent assays, and for this reason, large numbers of consistent replicate devices 
are generally required for blood-based research applications. Due to the single requirements and 
large number of required replicate devices, application of complex multilayer fluidic systems to 
blood handling is challenging when restricted to traditional fabrication methods. This chapter 
assesses the scalability of the fabrication technique outlined in chapter 2, investigating the 
practicality of fabricating the large quantities of single use disposable devices required for replicate 
bioassays. This work facilitates the implementation of a biological study, investigating the 
hemocompatibility of common on-chip control components, lifting gate pneumatic microvalves, 
paving the way for point of care blood handling devices. This work demonstrates that biological 
research applications utilising complex multilayer microfluidic structures are practically possible, 
given removal of their usual fabrication overheads.  
The aim of this thesis is work toward facilitating realisation of the full potential complex multilayer 
microfluidic systems have been predicted to achieve. To this end, this thesis investigates a 
fabrication method intended to facilitate practical realisation of complex multilayer microfluidic 
structures. Application of this fabrication method is explored in the context of real-world 
problems, assessing the practicality, adaptability and scalability of the method. Finally, the method 
is used to fabricate complex multilayer microfluidic systems in volumes required to enable 
biological studies, facilitating insights into the use of common multilayer control components for 
handling complex biological samples. This thesis demonstrates that overcoming the fabrication 
overheads generally associated with complex multilayer microfluidics does significantly improve 
accessibility to the advantages they offer. It is possible that removal of the fabrication roadblock, 
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and the associated increase in accessibility will enable more widespread acceptance of complex 
multilayer microfluidics. however, insights gained in the course of this work have identified other 
potential factors limiting complex multilayer microfluidics from reaching their full potential, with 
future work suggesting possible avenues towards their resolution 
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CHAPTER 2: Fabrication of complex PDMS microfluidic structures and embedded 
functional substrates by one-step injection moulding 
 
Chapter 1 identified the various advantages associated with complex multilayer microfluidic 
structures, but identified that the full potential predicted for complex multilayer microfluidics has 
yet to be realised, with little evidence of their widespread application outside niche lab 
environments. The hypothesis being pursued in this thesis is that a major barrier to widespread 
uptake and advancement of complex multilayer microfluidic systems is that the techniques 
required in their fabrication tend to be complex, labour intensive and generally don’t scale well. 
While numerous advances have been made in application of multilayer complex microfluidics 
systems in recent years, the fabrication techniques employed in realisation of these systems have 
not advanced along with their application. Multilayer device fabrication often requires specialised 
and somewhat limiting mould fabrication techniques [40], alignment and bonding of multiple 
layers [40, 41], or sacrificial structures that require mould removal [42]. In addition, challenges 
associated with fabrication of these devices sometimes scale along with device complexity, as 
effects such as thermal expansion and alignment of multiple layers of soft elastomer scale with 
both overall device, and minimum feature size [26]. Due to the difficulty inherent to these kinds 
of fabrication techniques, complex multi-layer microfluidic systems are generally limited to 
applications suited to low-volume production, such as high-investment research platforms, or re-
usable devices.  
This chapter investigates whether it is possible to develop a technique which can utilise the 
advantages of multilayer complex microfluidic devices, while minimising the negative aspects 
associated with fabrication of these systems. In this chapter, I introduce a fabrication process that 
allows simplified fabrication of microfluidic structures containing complex multilayer geometry. 
This work is intended to allow integration of complex control components, such as pneumatic 
microvalves, as well as allowing integration of functional components, such as permeable 
membranes and electrochemical sensors used in cell culture platforms.  
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The majority of this chapter is in the form of a published journal article, which outlines a fabrication 
method that can achieve these requirements, allowing fabrication of complex multilayer 
microfluidic structures using a simple and robust fabrication process. This method is validated in a 
proof of concept capacity with fabrication of normally closed lifting gate pneumatic microvalves 
for metered flow control, as well as a 3D cell culture platform, culturing two distinct cell types on 
either side of an integrated permeable membrane. Moulds used in this work are fabricated using 
standard photolithographic processes, or stereolithography based 3D-pinting techniques. 
Alignment structures can be included in the design, reducing the fabrication complexity to a single 
step for valve-based designs, or a two-step process if integration of functional components is 
required.  
 
The outcome of this work highlights that fabrication of complex multilayer microfluidics can be 
greatly simplified, overcoming numerous challenges associated with traditional methods used to 
fabricate microvalves [43], or multilayer membrane structures [28]. A fabrication method is 
outlined, allowing rapid and reliable fabrication of common complex multilayer microfluidic 
structures, and demonstrating this in a proof of concept capacity.  
It is anticipated the level of simplification offered by this fabrication method will allow routine 
fabrication of complex multilayer microfluidic structures, allowing their application, and thus the 
advantages that they allow, to be applied to numerous applications that would otherwise be 
impractical when dependant on traditional fabrication techniques. 
The proof of concept applications demonstrated in this chapter only contain a subset of complex 
multilayer components that may be required. Coming chapters will explore the practicality of this 
fabrication technique when applied to real world problems, investigating integration of more 
complex fluidic control components, active biosensor devices, and processing of complex 
biological samples, validating the benefits of the technique. In addition, the scalability of the 
fabrication technique will be explored, validating practicality of fabricating large quantities of 
replicate devices, as required for meaningful biological experiments. 
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As further work beyond the scope of this doctorate, I would suggest further exploration of the 
scalability of this fabrication technique in the context of commercial injection moulding 
approaches. Additionally, as PDMS is often not considered a favourable material for commercial 
application [44], There are various injection mouldable elastomer materials [45] that may be suited 
to fabrication with using method, allowing the mass production capacity that is required to realise 
practical point-of-care commercial application. 
This work was the result of a collaborative project with the Australian centre for blood diseases in 
Melbourne, the work related to this chapter has been peer-reviewed and published in: RSC 
Advances 
The paper can be obtained via the DOI:  10.1039/C6RA20688C [29] 
 
 
My role in this work was to conceptualise, design and iteratively improve the fabrication 
technique, fabricate microfluidic systems, run characterisation and cell culture experiments, and 
write the manuscript. Others assisted with manufacture of the support equipment, assisted with 
experimental design, and directed the biology. My leading role in this research is reflected in my 
being listed as first author.  
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one-step injection moulding†
C. Szydzik,a B. Niego,b G. Dalzell,a M. Knoerzer,a F. Ball,ac W. S. Nesbitt,ab
R. L. Medcalf,b K. Khoshmanesha and A. Mitchell*a
We report a novel injection moulding technique for fabrication of complex multi-layer microﬂuidic
structures, allowing one-step robust integration of functional components with microﬂuidic channels,
and fabrication of elastomeric microﬂuidic valves. This technique simpliﬁes multi-layer microﬂuidic
device fabrication, while signiﬁcantly increasing device functionality. We demonstrate functional
component integration through robust encapsulation of porous polyester membranes, in the context of
an in vitro research platform intended to facilitate Blood Brain Barrier (BBB) research. We also
demonstrate the fabrication of normally-closed, pneumatically actuated elastomer valves, integrated
using the same one-step process. These valves are demonstrated in the context of variable ﬂow resistors
used to modulate ﬂow in a pressure driven system.Introduction
Microuidics has ourished in recent years as an emerging
technology for addressing a wide range of research applica-
tions.1–5 Perhaps most notably, microuidics has shown
signicant promise in revolutionising the biomedical eld.6–9
Hybrid microuidic devices have been reported incorporating
integrated structures such as electrode arrays,10 permeable
membranes,11 micro-valves12,13 and other functional structures,
enabling complex lab-on-a-chip research platforms and point-
of-care devices. Numerous microfabrication techniques have
been reported for the realisation of microuidic devices. These
commonly use the material polydimethylsiloxane (PDMS) due
to its favourable chemical, mechanical, and optical properties,
as well as its inherent biocompatibility.4,14,15
Methods for eﬀective and reliable fabrication of complex
multi-layer PDMS microuidic structures incorporating func-
tional structures such as valves, pumps, mixers, membranes
and electrodes are crucial for further development of point-of-
care and lab-on-a-chip devices. One key challenge is to achieve
multiple microuidic channels on diﬀerent vertical planes as
well as vertical interfaces between those channels without
prohibitive fabrication complexity.elbourne, VIC 3001, Australia. E-mail:
sh University, Melbourne, Australia
s (IONAS), University of Applied Sciences
tion (ESI) available. See DOI:
94Reported fabrication techniques for realising such complex
structures can be divided into three primary categories. The rst
category relies on sequential traditional 2D microfabrication to
achieve multi-layer systems.14,16–19 This approach has been the
mainstay for realisation of complex microuidics for over
a decade, however while the devices have steadily increased in
complexity, this fabrication technique has not evolved signi-
cantly in the passing years.4,11,13,20,21 While layering of 2D
microfabricated structures is appealing due to its maturity,
complex systems oen require multiple manual alignment and
bonding processes, which require great skill, making them
unsuitable for high volume fabrication.
The second category of fabrication that can achieve multi-
layer structures is casting of PDMS around a 3D sacricial
structure, which is later removed or dissolved.22–25 This
approach eliminates the alignment and bonding issues of
layered approaches, however these methods oen require
complex protocols involving removal of the sacricial structure,
which can limit the geometry, impact yield, or again, require
skilled manual processing. The third category that has shown
particular promise is the mould based ‘membrane sandwich’
approach, rst presented by the Whitesides research group.26
This fabrication technique simplies the fabrication of layered
channel structures by sandwiching PDMS pre-polymer between
a patterned wafer based mould and a passivated PDMS mould.
This approach has the advantage of simplifying processing and
oﬀers simple mould removal. However, while fabrication tech-
niques have been developed along similar lines,27 there are few
reports of complex microuidic devices realised using this
approach, and it would appear that this technique has not been
widely adopted and developed by the community.This journal is © The Royal Society of Chemistry 2016
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View Article OnlineIn this paper, we present an enhanced membrane sandwich
based microuidic fabrication technique, which enables
accessible monolithic integration of complex microuidic
structures such as valves, as well as hybrid integration of various
functional elements, such as commercial porous membranes
used as interfaces between microuidic channels on diﬀerent
vertical planes. This one step process realises multi-layer
microuidic structures utilising reusable moulds fabricated
with high-resolution photolithography as well as rapid and
exible direct 3D printing. We demonstrate the utility of our
approach through realisation of an in vitro platform simulating
the brain blood barrier, and also pneumatic valves, which can
regulate pressurised uid ow.
Concept
Consider the situation illustrated in Fig. 1. If two complemen-
tary moulds are placed in contact and PDMS pre-polymer is
injected between them, then small voids between the moulds
will be lled with PDMS, allowing two independent channels to
be formed, which are isolated vertically by a PDMS membrane
of controlled thickness. Suﬃciently thin membranes could be
realised to allow pneumatic distortion in order to achieve
valves. If the two moulds are designed to make contact and are
pressed together rmly while injecting and curing the PDMS, it
should be possible to exclude the PDMS from between the two
moulds that are in contact, creating vertical interfaces between
the microuidic channels on diﬀerent layers, allowingFig. 1 Conceptual illustration of PDMS injection moulding fabrication
technique. (A) Complementary mould halves are initially loaded with
a functional substrate for integration, (B) the moulds are then brought
into contact and clamped, (C) degassed PDMS is injected through an
opening and ﬁlls voids between the mould structures. The mould
assembly is then placed in an oven at 70 C for one hour until cured (D
and E) upon removal of the mould structure the resultant double sided
PDMS slab is cut to size, and channels on either side of the slab are
sealed with glass slides.
This journal is © The Royal Society of Chemistry 2016controlled interconnects or isolated overpasses as required.
Functional structures could also be embedded within the PDMS
block and interfaced to the microuidic channels from both
sides.
Fig. 1 conceptually illustrates the fabrication technique with
Fig. 1A–F, illustrating the two mould halves being automatically
aligned by peg and hole structures in the mould. The moulds
are brought into contact, PDMS is injected to ll voids and
create a PDMS slab, followed by mould release and nal chip
assembly.
Fig. 2A–D illustrate how prefabricated functional structures
can be integrated into microuidic systems using this fabrica-
tion technique. Complementary mould structures are posi-
tioned to sandwich an aligned prefabricated functional device,
in this case a porous membrane, to achieve a uidic channel co-
culture chip.11 The complementary mould structures are
brought into contact, applying pressure to both sides of the
sandwiched device. PDMS is then injected into the mould
structure to ll the voids, fully encapsulating the device with the
exception of the area excluded by pressure with the raised
channel structures within the mould. This approach allows for
robust integration of the prefabricated device, interfaced to the
microuidic channels within the PDMS slab.
This fabrication technique can also be applied to realise
robust monolithic double-layer functional structures, including
pneumatic valves and pumps. Fig. 3A–D illustrate the concept
used to fabricate normally-closed, pneumatically actuated
valves28,29 The complementary mould halves are initially self-Fig. 2 Concept for integration and encapsulation of prefabricated
functional components. (A) Transwell permeable support membrane is
placed on a point of intersection of the microﬂuidic mould structures,
(B) the complimentary mould structures are then brought into intimate
contact and clamped, (C) PDMS is then injected through an opening
and ﬁlls the voids between moulds, (D) during this process PDMS
inﬁltrates all areas of the membrane not mechanically compressed,
resulting in clear areas at the channel intersection and mechanically
encapsulated areas without.
RSC Adv., 2016, 6, 87988–87994 | 87989
Fig. 3 Concept for fabrication of active elastomer structures. (A) The
mould halves are designed so as to not quite contact at the location of
the valve. (B) The mould halves are again brought into contact leaving
a narrow void in the region of the valve, (C) PDMS is injected forming
a membrane between the two channels, (D) the valve gate can be
actuated through application of negative pressure in the actuation
chamber.
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View Article Onlinealigned and brought into contact. A spacer structure, either
directly integrated into the mould or added during moulding
depending on the mould fabrication technique used, keeps the
moulds separated. The top and bottom moulds are thereby
dened such that a certain gap is maintained between the top
and bottom channels, allowing injected PDMS to ll the void
and form a membrane between them.Mould fabrication
In this work, moulds have been realised utilising various
microfabrication methods. Standard photolithography micro-
fabrication techniques have been used to create wafer-based
moulds for high-resolution applications, while larger struc-
tures for low-resolution rapid prototyping applications have
been fabricated using 3D printing.
In the case of photolithographically dened moulds, at least
one of the mould halves must be optically transparent to allow
manual alignment of complementary channels. For this reason,
one mould half was patterned onto a 3-inch 2 mm thick boro-
silicate glass substrate, with the corresponding half patterned
on a 4-inch silicon wafer substrate. A borosilicate substrate was
used as the top mould as it is optically transparent, allowing for
manual alignment. A thickness of 2 mm was used to ensure
structural integrity and facilitate the drilling of a 4 mm Luer-
connector interface hole for PDMS injection. A 4-inch, 500 mm
thick silicon wafer was used as the bottom substrate as silicon
has better photoresist adhesion properties than glass. SU-8 3050
series photoresist (MicroChem Corp) was used to produce87990 | RSC Adv., 2016, 6, 87988–87994channel mould structures with a height of 200 mm. The silicon
mould half is coated with a 20 nm titanium adhesion layer,
followed by a 200 nm gold layer applied using sputter coating.
This provides a non-reactive, passivated surface, which facili-
tates ease of mould release. Upon completion, the two
substrates are sandwiched, as outlined in Fig. 1. The 4 mm hole
in the top mould half allows coupling with lure type syringe
connectors, highly degassed PDMS is introduced through this
opening, and the entire structure is clamped and placed in an
oven at 70–80 C to cure. Aer curing, the two mould halves are
carefully opened. The cast PDMS structure begins to separate
from the mould spontaneously due to diﬀerential thermal
contraction of the mould and PDMS, releasing from the
passivated mould half rst. The slab can then be cut to size and
peeled from the unpassivated mould half and the de-moulded
PDMS part can then be permanently bonded using oxygen
plasma treatment to sealing glass slides. For further informa-
tion on injection moulding protocol see ESI S1.† The use of
standard photolithographic microfabrication techniques allows
for fabrication of high-resolution structures, however the
fabrication process is labour-intensive and requires cleanroom
facilities.
In contrast, 3D printing can be used to directly print
complementary mould structures.25,30 This was achieved using
a Projet 7000 HD 3D Printer (3DSystems Rock Hill, South Car-
olina) using the photo curable polymer VisiJet® SL Clear
(3DSystems Rock Hill, South Carolina). Structures printed using
this material require a post print processing step25 in order to
successfully mould PDMS. This approach allows rapid proto-
typing when very high-resolution structures are not required,
with minimum dimensions dened by the resolution of the 3D
printer. In the case of the Projet 7000 3D Printer, 100 mm
structures can be fabricated in a reproducible manner. Use of
3D printing, while only applicable for low-resolution structures,
greatly simplies the fabrication process. 3D printing allows for
fabrication of vertically tapered structures of varied height,31
such as the otherwise drilled 4 mm Luer-connector interface
hole as well as alignment pins and matched wells. These
alignment structures can be fabricated directly into the mould
structure, and can be used to self-align the mould structures,
eliminating the requirement for manual alignment, and simi-
larly the requirement for optically transparent substrates.
Demoulding of the PDMS from the 3D printed moulds was not
spontaneous and required manual removal of the PDMS part,
this could be due to various factors, such as the diﬀerent
thermal characteristics of the material, as well as lower curing
temperature required to avoid mould damage, the absence of
a passivated surface, or due to the slightly textured surfaces that
result from the 3D printing process. However, manual de-
moulding was relatively straightforward due to the larger
feature sizes of the 3D print moulded parts.
Results
The technique presented in this paper produces monolithic
double-layer PDMS structures, and robust integration of func-
tional structures, fabricated using a one-step process, allowingThis journal is © The Royal Society of Chemistry 2016
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View Article OnlinePDMS to form as a singular slab. Being a single block of PDMS,
this monolithic structure is capable of withstanding high
pressure and mechanical forces when compared with bonded
multi-layer structures. Utility of this technique was veried
through realisation of an in vitro microuidic co-culture plat-
form with integrated Transwell permeable support cell culture
scaﬀold structures (Corning Inc.) useful for various organ-on-a-
chip research platforms11,32–35 and also normally-closed pneu-
matically actuated valves, similar to previous examples from the
literature.28,29Encapsulation of Transwell permeable supports
Application of this technique results in robust integration of
Transwell membranes, similar in function to those integrated
into other microuidic systems using standard lamination
techniques,36 however embedded in a more robust structure.
Fig. 4 shows a microuidic research platform fabricated
using our novel technique, similar in concept to the in vitro
blood brain barrier (BBB) microuidic model demonstrated byFig. 4 Shows a Transwell permeable support fully encapsulated in
PDMS, in the context of an in vitromodel of the blood brain barrier. (A)
A tissue culture research platform fabricated using the elastomer
injectionmoulding technique. (B and C) Schematic and cross sectional
illustration of the membrane area, illustrating the membrane location
within the device. (D and E) The point at which the two channels
intersect, allowing access to both sides of the permeable support,
images obtained using scanning electron microscopy. (F) Represen-
tative image of a confocal microscope, demonstrating a monoculture
of human endothelial cells cultured within the device; ﬁlamentous
actin in red, nuclei in blue. (G and H) Phase contrast images of
endothelial cells and astrocytes cultured within the micro-channels, as
part of a co-culture system.
This journal is © The Royal Society of Chemistry 2016Booth and Kim 2012.36 We established a contact model of the
BBB in our device through co-culture of primary human brain
microvascular endothelial cells (ACBRI 376, Cell-Systems
Corporation, Kirkland, USA) together with human trans-
formed foetal astrocytes (a cell-line termed SVG,37 Burnet
Institute, Melbourne, Australia), on opposite faces of the
embedded membrane. Co-culture was achieved using processes
outlined in our previous work38 adapted for culture within
a microuidic ow based environment, similar to the process
outlined in ref. 36. In brief, endothelial cells are seeded into
a bronectin-treated (Cat. # F1141, Sigma-Aldrich, Australia)
channel and allowed to adhere for 2–4 h. The device is then
ipped and astrocytes are introduced into the channel inter-
facing the opposite side of the membrane. Cells are subse-
quently grown to conuence for 24–48 h under shear stress of 1
dyn cm2 prior to experimentation. A detailed culture protocol
is specied in ESI S2.† As a major improvement to similar ow
devices36 or to static BBBmodels,38,39 our platform is designed to
allow high-resolution microscopic access to both sides of the
integrated membrane, enabling real-time monitoring of either
cell type within the co-culture; since the chip is symmetrical and
horizontally opposed, a simple rotation over a microscope
objective becomes possible.
Fig. 4 shows a 3 mm pore Transwell permeable support
integrated with microuidic channels and encapsulated within
PMDS. Fig. 4C illustrates a cross section of the membrane area;
the at area has been compressed by contact between the two
moulds, while areas of membrane not compressed during
moulding extend into the PDMS slab and are fully encapsulated.
Scanning electron microscope images, Fig. 4D and E further
demonstrate how the channels cross at this intersection point
with the membrane, forming a permeable barrier between
channels. PDMS pre-polymer uid has a low surface tension
and can easily inltrate very thin gaps. This assists the encap-
sulation process by fully inltrating the individual pore struc-
tures of the Transwell support in areas of the membrane that
are not pressed against the mould during injection moulding,
as seen in the lower right of Fig. 4E. This process however does
not occur in areas of the membrane which are pressed against
the mould structures, as can be seen in the at region on the top
le of Fig. 4E, demonstrating that with this technique, it is
possible to choose where the PDMS will inltrate and where it
will be excluded. Gas bubbles trapped at feature edges or small
void features (such as membrane pores) can be avoided by
degassing PDMS pre-polymer under high vacuum conditions
prior to injection. Once thoroughly degassed, the pre-polymer is
able to absorb small bubbles prior to cure, resulting in defect
free casting.
Finally, as shown in Fig. 4F–H, our channels are fully
compatible with cell growth and micro-imaging. Fluorescence
confocal microscopy (Fig. 4F; Nikon A1r+ confocal microscope)
demonstrates actin laments and nuclei of endothelial cells
cultured on the porous membrane embedded within our device.
Furthermore, as shown by phase contrast microscopy (Fig. 4H),
both endothelial cells and astrocytes reach conuence within
the micro-channels and cover the entire channel and
membrane areas. Hence, our model is well-suited for biologicalRSC Adv., 2016, 6, 87988–87994 | 87991
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View Article Onlineexperiments not only in the context of the BBB, but also for
numerous other applications. Additional details regarding cell
culture protocols are included in ESI S2.†Fig. 6 (A) Application of the pneumatically actuated on chip valves in
use as ﬂow regulators of pressure driven ﬂuids in a droplet slug based
system. This system is an initial proof-of-concept prototype utilising
these valves to actively modulate the component of coloured waterNormally-closed pneumatically-actuated elastomer valves
Application of this technique results in robust elastomer
double-layer structures, and as a proof-of-concept was applied
in the context of normally-closed pneumatically actuated elas-
tomer valves, similar in principle, to previous reports,28,29
however, with an inherently more robust monolithic structure,
and signicantly simplied fabrication process.
As with many normally-closed elastomer valve approaches,
undesirable irreversible bonding of the valve gate to the channel
sealing substrate can occur. During proof-of-concept experi-
ments, this bonding was avoided by selective PDMS passivation
using manual application of ink to the valve gate followed by
post bonding ethanol wash out.40 To avoid this bonding on
a larger scale, and with increased reproducibility, various other
solutions such as valve actuation prior to bonding,28 or selective
surface de-activation41 can be applied, while the problem can
also be avoided using reversible pressure bonding with a clamp
structure.Fig. 5 Pneumatically actuated, normally-closed elastomer valves
fabricated using PDMS injection moulding with direct 3D printed
mould structures. (A) Shows a proof-of-concept prototype micro-
ﬂuidic system used to demonstrate valve functionality, (B) shows
a conceptual illustration outlining the functional principal of the valves,
(C–F) demonstrate operation of these valves as ﬂuidic resistors. Water
is introduced at the primary inlet using a syringe pump, and the dyed
inlets are fed by reservoirs maintained at slightly positive pressure.
Valve actuation chambers are manually pressurised using a syringe to
produce full or partial opening of blue and red dye gates.
dispensed into each droplet, and is planned for investigating the
eﬀects of various drug concentrations and combinations on the
morphology of blood cells under ﬂow, (B–E) show mixing of reagents
within a slug at various time points.
87992 | RSC Adv., 2016, 6, 87988–87994Fig. 5 illustrates validation of these valves, Fig. 5A shows an
assembled chip, while the cross section in Fig. 5B conceptually
demonstrates operation of these valves. Pressurising the actu-
ation chamber relative to the valve gate will close the valve;
while evacuating the actuation chamber opens the valve.
Applying an intermediate pressure can result in a partially open
valve with nite uidic resistance. In this proof-of-concept
demonstration, this pressurisation and evacuation is achieved
manually using a syringe.42 Fig. 5C–F qualitatively illustrate the
valves in use as variable ow resistors, controlling the conuent
ow of water, and coloured water with food dye (further detail
provided in ESI S3 and Video 1†).
Fig. 6 illustrates valves fabricated using this method modu-
lating the concentration of reagents added to uid slugs to
allow rapid microuidic mixing. In this arrangement, valves can
be used to apply known ratios of uid to the droplet stream, or
fully isolate the dye channel, as would be required in research
platforms investigating the eﬀects of known volumes of drug to
blood droplets. Fig. 6A shows the system congured as in Fig. 5,
however with the addition of an immiscible uid ow from the
top channel, operation of the system is demonstrated in ESI
Video 1.†Discussion
Most reported fabrication techniques for encapsulation of
functional substrates within PDMS, or fabrication of elastomer
valves, involve the stacking and bonding of multiple layers ofThis journal is © The Royal Society of Chemistry 2016
Paper RSC Advances
Pu
bl
ish
ed
 o
n 
08
 S
ep
te
m
be
r 2
01
6.
 D
ow
nl
oa
de
d 
by
 R
M
IT
 U
ni
ve
rs
ity
 L
ib
ra
ry
 o
n 
15
/0
1/
20
17
 2
2:
08
:2
1.
 
View Article OnlinePDMS thin lms patterned with channel structures. Valves are
commonly fabricated using this method,28 and thin structures
can be integrated by lamination between these PDMS lms, so
long as they are thin enough to allow suﬃcient adhesion of
PDMS layers.32 While these approaches are well-established,
they are time-consuming, labour-intensive and error-prone, as
all layers must be fabricated, aligned and bonded individually.
These techniques can also lead to platforms that are prone to
failure due to leakage caused by various defects, which can
occur under diﬀerent circumstances, including when the layers
are not correctly aligned and wrinkles form, when debris is
caught in between the two layers, when a pressure diﬀerential
between the closed channel and ambient environment is
signicant enough to delaminate the PDMS layers, or a combi-
nation of these factors.43
While bonded multi-layer integration of devices within
PDMS is limited to devices thin enough to allow for mechanical
deformation of the PDMS to form a seal around the edges, this
technique fully encapsulates all surfaces of the device not
within the deliberate exclusion zones of the mould, and for this
reason is not limited to integration of thin devices. Comparing
the practicality of 3D printed and photolithographic moulds:
fabrication using 3D printing allows rapid and arbitrarily
recongurable prototyping and automatic mechanical mould
alignment, however resolution and surface smoothness is
limited by the printer used, various materials used in stereo-
lithography require post-print processing steps and mould
release is more challenging with these materials. Photolitho-
graphically dened moulds allow signicantly higher resolu-
tion, however require cleanroom fabrication facilities, and
make multi-layer moulds cumbersome, limiting the options for
automatic mechanical alignment and thereby requiring trans-
parent substrates.
Another consideration is the ease with which the PDMS
structure can be de-moulded. In our experiments de-moulding
of photolithographically dened moulds begins spontane-
ously, driven by thermal contraction, whereas the 3D printed
moulds required manual removal of the part, however this was
relatively straightforward. It is anticipated that design of the
mould, cooling protocol and selective surface treatments could
be optimised to enhance and control the thermal contraction
de-moulding process. It may also be possible to inject gas into
the mould to make the cooling and de-moulding even more
rapid for scaling to automatic and rapid throughput for both
photolithographic and 3D printed moulds. These investigations
will be pursued in future work.
Conclusions
We have shown a practical method for the fabrication of
monolithic microuidic devices with complex 3D structures.
This method allows for the integration of devices that enable
complex functionality for microuidic systems. This method is
also suited to rapid prototyping and reduces fabrication error
compared to established methods, allowing for more reliable
and complex microuidic chips to be realised in a short time.
This technique allows for reduction in fabrication complexity,This journal is © The Royal Society of Chemistry 2016while allowing for increase in functional complexity, and could
be applied to signicantly simplify the fabrication of complex
valve based research platforms such as those seen in large scale
integration approaches.12,44 Future research will investigate
hybrid integration of various modular components such as
membranes, electrodes, piezo-actuators, heaters, pressure
sensors and biosensors within lab-on-a-chip platforms, with the
potential of retaining high-resolution optical access. This
technique can also take advantage of the emergence of high
resolution 3D printing, enabling reusable moulds for very
complex systems incorporating both valve membranes and
hybrid integrated elements to be realised rapidly and reliably
and should thus mark a major acceleration in the application of
microuidic platforms.Acknowledgements
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CHAPTER 3: Complex microfluidics for photonic biosensor applications: Point of 
care, and sophisticated research platforms.  
 
The overall hypothesis of this thesis is that overcoming fabrication challenges generally associated 
with complex multilayer microfluidic systems, will greatly increase their accessibility, therefore 
providing a pathway for widespread acceptance. The previous chapter outlined a fabrication 
method intended to simplify fabrication, while allowing scaling on-chip circuit complexity and 
functionality, it was shown that membranes and valves could be fabricated with relative ease, 
however it is not yet known whether this apparent advancement in fabrication of complex 
microfluidics will actually benefit real world applications.  In particular, it is postulated that a 
sufficiently simplified fabrication technique, reducing iterative cyclic development time will enable 
accelerated prototype development which can enable researchers unfamiliar with multilayer 
microfluidics to rapidly adopt this technology. 
This chapter explores this hypothesis by engaging in short term collaborations with two 
researchers who are not experts in microfluidics and rapidly advance their research using complex 
microfluidics.  The chosen field of application for this chapter is photonics biosensors.  Photonic 
biosensors are among the most sensitive biomarker detection technologies [46], and for this 
reason would be well suited to point-of-care diagnostic applications, and sophisticated research 
platforms. As a caveat, this kind of biosensor usually requires careful fluid handling strategies, 
requiring a series of carefully isolated fluids introduced in a defined sequence, which presents a 
challenge for point-of-care application. In addition, photonic biosensors require careful and 
precise environmental control. Photonic biosensors are exceedingly sensitive to bulk refractive 
index changes within the surrounding media, as can be introduced for example through changes 
in temperature and osmolarity of the media. The requirement for fluidic isolation and well 
controlled sample handling necessitates some manner of fluidic automation capable of 
environmental control to enable practical point-of-care application.  
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The work in this chapter is presented in the form of two journal articles specifically in the context 
of waveguide based, automated point-of-care sensing of dissolved analytes (Section 3.1), and 
plasmonic based monitoring of the secretion of single cells (Section 3.2).  
 
The outcome of this work has demonstrated that removing the fabrication bottleneck generally 
associated with complex multilayer microfluidic systems, through deployment of the fabrication 
technique outlined in chapter 2, allows access to applications otherwise considered prohibitively 
difficult when limited to traditional fabrication methods.  
Section 3.1 has demonstrated on-chip fluid automation approaches adapted to provide assay 
automation of an integrated photonic biosensor, with rapid fabrication turnaround offered by the 
technique outlined in chapter 2 allowing rapid integration of various control components.  
Section 3.2 has shown adaptation of the fabrication technique to include well defined membranes 
for sophisticated environmental control of a single cell analysis platform, demonstrating the 
techniques capacity for rapid reconfigurability. 
The Applications explored in this chapter have demonstrated that the fabrication technique 
outlined in chapter 2, does provide the fabrication timeframes required for rapid prototyping, 
allowing iterative design improvements, with turnaround within a couple of days. This proved 
crucial as designs were iteratively improved to deal with various unforeseen issues. Valve 
geometry was one such issue, it was necessary to scale the valves in an effort to condense complex 
fluid handling structures into the real-estate available, this resulted in initial performance short of 
that expected. Adhesion of the valve gates with the channel floor was one of the primary issues 
encountered as a result of scaling, as well as valve gates closing with sufficient speed to allow 
efficient pump operation. While it was possible to avoid adhesion through improvement of valve 
geometry, closing speed was improved through application of positive pressure to actively close 
valve gates. This led to additional issues, with positive pressure actively permeating gas across 
valve membranes to form bubbles within the system, requiring additional re-design of the fluidic 
systems and careful control of the pressure levels applied.  The speed and reliability of the platform 
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introduced in Chapter 2 enabled the entire study of Section 3.1 to be completed during a 6 month 
visit to the ICN2 labs with Laura Lechuga and the study of Section 3.2 to be completed remotely in 
collaboration with EPFL even though 4 iterations of the microfluidics were required to achieve the 
final outcome.  
Overall the fabrication approach of Chapter 2 has demonstrated significant benefit for research 
prototype development. However, to really prove value in point-of-care context, the platform 
should be demonstrated to function with more complex biological samples, for example with 
whole human blood and with repeatability and reliability required for clinical trials and ultimately 
mass deployment. 
    
During the scope of this work, all pneumatic driven on chip components were actuated either 
manually for simple static applications, with a syringe or manual pump, or for complex dynamic 
automated applications, through implementation of a custom-built programmable valve driver 
system. The valve driver is a pneumatic system with two pressure vessels held one at higher and 
one lower than ambient pressure, with solenoid valves switching between the two and supplying 
this to on-chip control elements. it became apparent during this work that access to this valve 
driver represented an additional barrier for continued use of dynamic automated microvalve 
based microfluidic technology.  
As further work beyond the scope of this doctorate, I would suggest development of a 
standardised automated programable control interface that can be readily deployed to end users, 
with a similar design rationale as a motherboard supporting a central processing unit. If such 
supporting equipment could be simplified and developed to the point that it was relatively cheap 
and easy to deploy, similar to a benchtop syringe pump, this may reduce the barrier for uptake of 
automated microvalve based fluid handling systems. 
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3.1 –  An automated optofluidic biosensor platform combining interferometric sensors and 
injection moulded microfluidics 
 
A primary factor limiting development and application of point-of-care diagnostic systems, is 
practical integration of biosensors with robust microfluidic handling systems, capable of 
automating assay processes required for operation [46]. As such, point-of-care application is 
identified as a field highly dependent on realisation of a simple, scalable and robust fabrication 
method, as required for high volume production. It is evident that point-of-care applications in 
particular would benefit from the automation and precision that complex multilayer microfluidic 
systems should provide.  
While various microfluidic automation approaches exist, most of those that achieve fluidic 
isolation depend on valving components that require complex and time-consuming fabrication 
techniques, unsuited to rapid fabrication and incompatible with mass fabrication techniques [12, 
19].  
The paper of this section investigates whether an automated fluid handling system utilising lifting 
gate pneumatic microvalves [41] can be fabricated with the technique explored in Chapter 2, and 
whether this fabrication technique allows prototyping with short turnaround time and hence 
allows rapid iterative improvement.  
This paper was the result of a collaborative project with the Nanobiosensors and bioanalytical 
applications group at ICN2 in Barcelona, the system was designed to facilitate point-of-care 
implementation of the Bimodal waveguide photonic biosensor developed by this group.  
The paper demonstrates that it is practical to integrate complex microfluidic devices fabricated 
with the method outlined in chapter 2, with an active photonic biosensor platform, using dynamic 
control components to actuate fluids required for automation of a complex immunoassay. 
The work related to this chapter has been peer-reviewed and published in: Lab on a chip 
The paper can be obtained via the DOI: 10.1039/C7LC00524E [30] 
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My role in this work was to design and fabricate fluidic systems, run biosensor experiments and 
write the majority of the manuscript. Others assisted with manufacture of the support equipment, 
assisted with experimental design, directed the surface functionalisation strategy employed and 
various other supporting roles. My leading role in this research is reflected in my being listed as 
first author.  
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A primary limitation preventing practical implementation of photonic biosensors within point-of-care plat-
forms is their integration with fluidic automation subsystems. For most diagnostic applications, photonic
biosensors require complex fluid handling protocols; this is especially prominent in the case of competitive
immunoassays, commonly used for detection of low-concentration, low-molecular weight biomarkers. For
this reason, complex automated microfluidic systems are needed to realise the full point-of-care potential
of photonic biosensors. To fulfil this requirement, we propose an on-chip valve-based microfluidic auto-
mation module, capable of automating such complex fluid handling. This module is realised through appli-
cation of a PDMS injection moulding fabrication technique, recently described in our previous work, which
enables practical fabrication of normally closed pneumatically actuated elastomeric valves. In this work,
these valves are configured to achieve multiplexed reagent addressing for an on-chip diaphragm pump,
providing the sample and reagent processing capabilities required for automation of cyclic competitive im-
munoassays. Application of this technique simplifies fabrication and introduces the potential for mass pro-
duction, bringing point-of-care integration of complex automated microfluidics into the realm of practical-
ity. This module is integrated with a highly sensitive, label-free bimodal waveguide photonic biosensor, and
is demonstrated in the context of a proof-of-concept biosensing assay, detecting the low-molecular
weight antibiotic tetracycline.
Introduction
Photonic biosensors enable cost-effective, highly sensitive,
and selective label-free detection of target biomarkers,1–3 they
require relatively simple support equipment and software to
operate and a minimal physical footprint.4 With appropriate
functionalisation strategies, these biosensors can be reused
multiple times5 and have been shown to be capable of exceed-
ingly low limits of detection.6,7 While photonic biosensors are
among the most highly sensitive biosensor technologies avail-
able,2 many of their other unique characteristics are highly at-
tractive for point-of-care applications, in which devices are
generally required to be compact, self-sufficient and simple to
operate while maintaining reliability, accuracy and reproduc-
ibility.8 Despite these advantages, several challenges exist
restricting practical adoption of photonic biosensors for
point-of-care devices.1 One of the most significant challenges
is fluid handling, as photonic biosensors generally require
complex flow handling protocols, with sequential application
of multiple reagents and a critical need for fluidic isolation.
Fluid handling becomes increasingly complex when advanced
assays are required, such as competitive immunoassays, com-
monly applied when the target analyte to be detected is of low
molecular weight and is present in very low concentrations,
as is the case with pesticides, toxins or antibiotic residues for
food control and environmental monitoring applications.9–11
The field of microfluidics has been proposed extensively as
a solution for point-of-care diagnostic devices for the
healthcare sector,8 and has attracted significant interest in re-
cent years.12–15 Microfluidic systems intended for point-of-care
application must employ simple, ideally automated operational
principles, and must maintain compatibility with scalable fab-
rication techniques suited to mass fabrication.8,13 As a result,
few of the fluid handling strategies commonly employed in
point-of-care devices are suited to the specific requirements of
photonic biosensors, lacking the necessary dynamic functional-
ity, fluid isolation performance and scalability. Further, al-
though integration of photonic biosensors with complex auto-
mated microfluidic systems could provide the level of precise
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fluid handling required for point-of-care, merging of these two
technologies is currently challenging due to fabrication com-
plexity, and control of the interfaces necessary for the fluid
handling protocols required to operate such sensors.
Numerous complex microfluidic fluid manipulation tech-
nologies exist in the literature capable of achieving on-chip
fluidic isolation. Digital microfluidics,16 droplet based micro-
fluidics17 and pneumatic valve based microfluidic systems18
are some of the common technologies employed to manipu-
late, isolate and mix precise volumes of fluid on-chip. Among
these technologies, pneumatic valve based microfluidic sys-
tems demonstrate the highest potential for flexible and scal-
able integrated platforms. Microfluidic automation of exceed-
ingly complex fluid handling protocols has been achieved
utilising pneumatic valve based systems for numerous appli-
cations,18 including lab-on-a-chip platforms,19–21 and biosen-
sors.22,23 Of particular interest, this technology has been ap-
plied to fluidic automation of photonic biosensors.24–26
While application of such automated microfluidic systems
provides the required fluidic isolation, a high degree of flexi-
bility, and on-chip fluidic control in a manner not otherwise
possible, fabrication of the valves required to operate such
devices is generally cumbersome, and integration can be-
come difficult to the point of impracticality.
We have recently begun to explore the possibility for com-
plex integrated microfluidics and integrated optics.27 We pres-
ent here an automated fluid handling module designed for
nanophotonic biosensors with complex valved microfluidics
realised utilising a simple one-step injection moulding tech-
nique,28 which can achieve complicated valved microfluidics
which significantly reduce fabrication complexity and have the
potential for scale-up mass manufacture. We demonstrate the
utility of this microfluidic by integrating it with a highly sensi-
tive bimodal waveguide photonic biosensor,4 and demonstrate
the functionality of the complete integrated system by
performing repeated automated competitive immunoassays for
the detection of an analyte of small molecular weight (the anti-
biotic tetracycline). The ability to realise such high quality
valved microfluidics while maintaining simplicity and scalabil-
ity renders complex automated microfluidics of the sort re-
quired for photonic biosensors practical. This work thus repre-
sents a major advancement in the development of practical
photonic biosensors for point-of-care applications.
Photonic background
This work harnesses the bimodal waveguide photonic biosen-
sor4 (BiMW) depicted in Fig. 1, a photonic interferometric
sensor design which has demonstrated an outstanding bio-
sensing sensitivity for the detection of diverse
biomarkers,29–31 down to exceedingly low target concentra-
tions in the atto-molar range.7 bacteria detection at few cfu
mL−1 (ref. 30) or hormone detection a few pg mL−1.32 Opera-
tion of this sensor is described in detail in previous publica-
tions,4 but for reference a brief description is provided here.
In these biosensors, monochromatic visible light is coupled
into the photonic chip through a single mode input wave-
guide (fundamental mode), this mode is then split between
two guided modes (fundamental and the first order mode),
with the same polarization, through an interface with a step
junction in the waveguide geometry. The surface of the bio-
sensor is passivated with the exception of a sensing window,
which is functionalised with a specific bioreceptor. Both
modes are propagating along the sensing area and their eva-
nescent fields interact with the biomolecules at the wave-
guide surface. The evanescent fundamental mode penetrates
less deeply into the sensing area, and can thus be used as
the reference. Any change in the refractive index of the sens-
ing area causes an interference pattern and in turn, a varia-
tion of the intensity distribution of the light exiting at the de-
vice output. By measuring the output light intensity
distribution, the sensor response can be determined.
Fabrication of the bimodal waveguide photonic biosensor
is achieved in a cleanroom facility using standard microelec-
tronics techniques as outlined in,4 silicon nitride (refractive
index 2.00) is used in the fabrication of visible wavelength
waveguides, with a silicon dioxide cladding layer (refractive
index 1.46). The bimodal waveguide is 3 μm in width, has a
rib of 1.5 to 3 nm and a thickness of 150 nm (single mode
zone) and 340 nm (bimodal zone). The active photonic area
of the chip surface is limited to the photonic sensing window
etched into the cladding within the bimodal segment of the
waveguide, with an area of 15 mm by 50 μm. Multiple devices
are fabricated at wafer level, and later divided into individual
chips containing 20 BiMW sensors each, separated by 250
μm. Photonic access is achieved through end-fire coupling
on the end of the device while output light is collected with a
multi-channel photodiode or CCD camera on the other end.
The sensor surface is functionalised through immobilisation
of a specific target, and thus, the selective biomolecular recogni-
tion which takes place results in a change of the refractive index
at the sensor surface, which perturbs the evanescent field and
can thereby be detected as changes in the interferometer output.
Fig. 1 Scheme illustrating the working principle of a bimodal
waveguide biosensor, showing the main components of the bimodal
waveguide photonic biosensor; inset top left shows how the
electromagnetic field associated with the light beam propagates
through the waveguide, while the bottom right inset is a photograph
of the chip, shown with a 1-euro coin for reference.
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Microfluidic subsystem integration
Microfluidic design considerations
As described above, a primary issue hindering development
of point-of-care photonic biosensor platforms is practical
integration with on-chip microfluidic systems, providing au-
tomated sample and reagent fluid handling 1. Photonic bio-
sensors generally require fairly complex fluid handling proto-
cols, with multiple fluids manipulated sequentially; in
addition, fluidic isolation is required in order to eliminate
cross contamination between regents, and flow conditions
must be reproducible. Sample volume is ideally kept to a
minimum, with channel geometry minimised in order to en-
sure an adequate mass transport to the sensor surface to
avoid unnecessary delays in the biointeraction. In addition,
for practical point-of-care applications, any integrated fluidic
system must be cheap to manufacture, with simple interfaces
and ideally utilise simple and scalable fabrication techniques
compatible with mass production.
Our previous work has primarily utilised simple micro-
fluidic systems fabricated using polydimethylsiloxane
(PDMS),4 a biocompatible material commonly used in the
fabrication of microfluidic devices.33 Fluidic isolation was
achieved externally through manual valve manipulation, and
samples were manually introduced to a sample loop and
flushed through the tubing using a syringe pump.
While numerous on-chip fluidic actuation technologies ex-
ist in literature, valve based approaches are the best suited to
providing fluidic isolation. Due to recent improvements in
fabrication techniques,28 it should be possible to adapt nor-
mally closed pneumatically driven on-chip valve based tech-
nologies23 to realise a sufficiently complex, but reliable,
valved microfluidic system to automate a photonic BiMW
biosensor.
Fig. 2 Schematic of the automated microfluidic module and its various components. Fig. 2A shows a CAD model of the reusable microfluidic
module reversibly bonded to the BiMW sensor with a clamp structure, which is fixed to the thermal stage of the setup with screws. Right is an
exploded view showing the two primary components, a PDMS interface slab irreversibly bonded to a double sided injection moulded PDMS slab,
and a clamping layer. Fig. 2B highlights locations of the primary fluidic reservoirs and overall alignment of the microfluidic and the photonic
sensor, while Fig. 2C shows an enlarged schematic of the various active microfluidic components, with features on the top surface of the injection
moulded PDMS slab shown in green and the bottom layer shown in blue.
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Microfluidic system overview
Fig. 2 presents a diagram of the fluid handling module pro-
posed for automatic operation of the BiMW sensor. Micro-
fluidic channels are patterned into either side of a thin PDMS
slab seen in Fig. 2A, utilising an injection moulding fabrica-
tion technique. This slab is bonded with a thicker PDMS
interface slab, biopsy punched with interfaces and reservoirs
of appropriate diameter as seen in Fig. 2B. The PDMS chip is
then placed over the BiMW sensor and its associated photo-
nic interface and thermal stage, and clamped in place as
outlined in.4 The module includes several gate valves to con-
trol the flow of the various fluids required for biosensing as-
says. These gate valves are multiplexed to minimise the num-
ber of external pneumatic actuators required. The module
also includes a single on-chip diaphragm pump to actuate
each of the fluids as selected by the gate valve assemblies. All
fluidic channels patterned into the module are 250 μm wide,
with exception of valve, pump and viaduct structures. The
top channels, shown as green in Fig. 2 are 160 μm deep,
while all primary fluidic channels patterned on the bottom of
the slab, and shown in blue, are 140 μm deep. 6 on-chip flu-
idic reservoirs, accessible through routing channels in the
top layer, are interfaced through 500 μm biopsy punched via-
ducts from the top to bottom layer. Further detail on func-
tional sub-units is presented below.
Normally closed pneumatically actuated gate valves
The normally closed pneumatically actuated gate valves are il-
lustrated in Fig. 2C. At the centre of each valve is a gate struc-
ture, a barrier of PDMS, 400 μm long and 100 μm wide, these
gates are normally lowered to close channels, and can be
pneumatically lifted to open the channel. This gate is pat-
terned as a protrusion on a thin elastic membrane (60–100
μm thick) which can be deformed. Above this membrane is
an oval shaped open channel which acts as an actuation
chamber, with a width of 350 μm, length of 750 μm and
channel depth of 160 μm. When this chamber is evacuated,
the elastomeric PDMS membrane deforms upward, lifting the
gate from the bottom of the channel, creating an opening in
the barrier and allowing flow across the valve gate. Positive
pressure is used to actively and rapidly close the valve gates,
and is critical to enabling rapid valve switching, required for
efficient pumping. In order to actuate and automate all on-
chip valves, a customised external support equipment and
software package was developed. This valve driver system
operates on a similar principal to those shown in various
pneumatically driven on-chip valve systems.34
The driver system interfaces with a control computer, and
utilises micro-solenoid valves (Burkert Type 6650-189292) to
switch between two reservoirs, maintained with an auto-
mated pressure regulation sub-system at defined relative
pressures of −900 mBar for actuation and +50 mBar for valve
closure. A Python script is used to rapidly switch individual
solenoid valves in sequences appropriate to operation of on-
chip control components.
Multiplexing valve assemblies
Fluidic multiplexing is required to minimize the number of ac-
tive valve control lines, and thereby to minimise external sup-
port equipment. It should be possible to achieve multiplexing,
while reducing the chance of fluidic contamination due to dead
volume in fluidic junctions, through minimisation of valve size
and by optimising valve and channel geometry. Multiplexing is
achieved using parallel valve assemblies as shown in Fig. 2C.
These assemblies consist of three gate valves, controlling the
flow through channels that connect with the on-chip fluid res-
ervoirs. These valves are operated symmetrically, with each of
the valves paired with a complementary valve on the opposite
assembly. Each assembly is addressed with its corresponding
valve on the pump, such that only one of the open pairs is aspi-
rated during pump actuation. These assemblies are designed
with an elongated hexagonal geometry, with valve gates placed
in a triangular configuration, minimising the distance between
valve actuation chambers and minimising fluidic dead volume
within the assembly. Running buffer reservoirs feed into the
central gate, facilitating washout of the assembly when
switching between reservoirs.
On-chip diaphragm pump
On-chip fluid propulsion is a critical function required to
achieve automation; valve based on-chip pump systems gener-
ally utilise peristaltic principles to achieve this.35 With the avail-
ability of the previously described gate valves, it is possible to
also consider a pneumatically driven diaphragm pump for fluid
actuation with active control of gate valves around this dia-
phragm, to control the direction of fluid flow. The on-chip pump
consists of a symmetrical chamber structure with two inlets, two
outlets, and a flexible diaphragm, illustrated in Fig. 2C while
utilisation of a dedicated membrane, using an 800 μm square
actuation chamber, provides propulsion. The desired inlet is ini-
tially opened, and the diaphragm is lifted, increasing the volume
of the pump chamber and drawing fluid from the inlet; the inlet
is then closed, the desired outlet opened, and the diaphragm is
forced closed, distending into the pump chamber and reducing
its volume, forcing the contained fluid through the open outlet.
Valve assemblies are positioned as close as possible to the
pump structure, so as to reduce fluidic volume of the connecting
channel, minimising required reagent volume and assay times.
Due to the paired actuation of the valve assemblies, diffusion of
fluids across open valve gates can contaminate the fluid within
the unused assembly. To avoid this and ensure pure sample or
reagent delivery to the sensor surface, it is necessary to purge the
volume of the assembly to waste when switching between ports
on opposite assemblies. This, as well as priming of all fluidic
lines, is done through the waste channel output of the pump.
Microfluidic fabrication
Fabrication of the microfluidic modules was accomplished
utilising a combination of the ‘membrane sandwich’ ap-
proach,36 and a novel PDMS Injection moulding technique,
previously described by our group.28 In brief, complementary
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mould structures are fabricated using standard photolithog-
raphy techniques or 3D printing. All fluidic channel struc-
tures to be in contact with the sensor surface are patterned
onto a bottom mould, while all actuation channels and via or
interconnecting channels are patterned onto a complemen-
tary top mould. Polydimethylsiloxane (PDMS) pre-polymer
(Sylgard 184 Silicone Elastomer – Dow Corning) is mixed with
curing agent with a weight ratio of 10 : 1 respectively, and
thoroughly degassed under vacuum. Degassed pre-polymer
composite is then introduced between aligned complemen-
tary mould structures. The assembled mould structure is
then placed into an oven for 1 hour at 80 °C, when cured, the
mould structures are separated and the PDMS slab (shown in
Fig. 2A) is extracted. A blank PDMS interface slab of approxi-
mately 4–5 mm thickness is then biopsy punched with appro-
priately aligned pneumatic interface holes (0.75 mm) and on-
chip fluidic reservoirs (4–6 mm). The actuation side of the in-
jection moulded PDMS slab is irreversibly plasma bonded to
the interface slab; this assembled PDMS module can then be
aligned over the sensor surface of the BiMW sensor and re-
versibly bonded. A thin (250–500 μm) PDMS cap can then be
placed over the top of the module, this layer has cut-outs
allowing access for pneumatic interface tubing, it is reversibly
bonded and prevents evaporation of fluid from the on-chip
reservoirs. The thin evaporation preventative layer can easily
be lifted at the edge of the assembly to allow access to the
on-chip reservoirs; small perforations can be made with a hy-
podermic needle in the areas centred on these reservoirs,
these perforations will seal due to the elastomeric nature of
the PDMS as long as the PDMS is flat, however they allow gas
transfer when a pressure differential is applied, equilibrating
pressure within the reservoirs. Finally, the assembled module
is clamped using screws between a polymethyl methacrylate
(PMMA) clamp layer and the BiMW setup outlined in ref. 4.
The physically realised PDMS device is presented in Fig. 3.
Microfluidic subsystem characterisation
To verify functionality of the microfluidic control systems,
each of the components was initially verified independently.
Fig. 3A and B shows these subsystems in operation with food
dyes verifying fluidic isolation, while the final integrated con-
figuration is shown in Fig. 3C. Low resolution microscopy of
the entire module in operation with food dyes illustrates the
Fig. 3 Imaging of the microfluidic subsystems. Fig. 3A shows a low-resolution microscopy image of the area illustrated in Fig. 2C imaged in opera-
tion with color dyes while bonded to a glass slide. Control components are labeled, with high resolution images of the multiplexing valve assembly
and pump inset including cross sectional cut of the pump structure. Fig. 3B shows integration of the microfluidic module with the BiMW sensor,
with channels highlighted with color dyes, while Fig. 3C shows an operational image of the module integrated with an active BiMW sensor.
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functionality of the multiplexing valve assemblies and pump
in Fig. 3A, where the running buffer is represented with yel-
low dye in central reservoirs, while other colours represent re-
agent and sample fluids, respectively. Supplementary Video-
1† demonstrates operation of the on-chip pump with food
dyes purged through the waste channel. Inset within Fig. 3A
includes higher resolution images of the pump and
multiplexing assembly structures, as well as a cross-sectional
cut of the pump structure, showing relative thickness of the
valve structural layers. This dissected valve geometry is ex-
plored in further detail in Supplementary Fig. S-1.† Fig. 3B
shows the microfluidic module aligned and reversibly
bonded with a BiMW sensor chip, assessing valve functional-
ity and verifying fluidic isolation. 3C shows the module inte-
grated with an active BiMW photonic sensor while in opera-
tion. The on-chip diaphragm pump was experimentally
demonstrated to achieve stable flow rates up to approxi-
mately 7.5 μL min−1. During Automated experimental proto-
cols flow rates of 1.5 μL min−1 and 6 μL min−1 were used for
sample flow and waste purging operations respectively.
Biosensing proof-of-concept
In order to assess the functionality of the microfluidic mod-
ule interfaced with the BiMW sensor, we have employed flu-
idic automation in the context of a complex competitive bio-
sensing assay requiring repetitive reference and competitive
analysis cycles.
As a proof-of-concept we demonstrate the detection of the
antibiotic tetracycline. Tetracycline is one of the most widely
used antibiotics, exhibiting a broad spectrum of antimicro-
bial activity against a variety of disease-producing bacteria.
Antibiotics are used extensively in human and veterinary
medicine, and also in aquaculture, in order to prevent or
treat microbial infections. Antibiotic residues from different
sources (household, pharmaceutical industry, and hospital)
enter into municipal sewage but they are only partially elimi-
nated at sewage treatment plants and as consequence, resi-
dues of these drugs and their metabolites are released into
the environment. The uncontrolled exposure to antibiotic res-
idues increases the appearance of antibiotic-resistant bacte-
ria, which represents a serious and growing human health
threat worldwide, because infections from resistant bacteria
are increasingly difficult and expensive to treat. Therefore,
due to its widespread use, monitoring of tetracycline levels is
important in numerous fields such as clinical diagnosis,37
food processing,38 and environmental pollutant monitor-
ing.10 Tetracycline has a low molecular weight (444.45) and is
often found in low concentrations (110 pg mL−1 in contami-
nated surface water and 400 pg mL−1 in contaminated
groundwater39), for these reasons competitive immunoassays
are well suited for its detection. In a competitive immuno-
assay format the chemical target to be detected, present in a
sample, competes for the antibody binding sites with a recep-
tor previously attached to the sensor surface. The sample
containing the chemical target to be detected is incubated for
a few minutes with a fixed quantity of the corresponding
antibody and then flowed on to the sensor surface. The sig-
nal is obtained by the interaction of the remaining free anti-
body of the incubated solution (sample + antibody) with the
receptor layer. Therefore, the signal is inversely proportional
to the concentration of the chemical target in the sample.
The bioreceptor layer is expected to be re-usable during vari-
ous analysis cycles by regeneration of the sensor surface, i.e.
by dissociating the receptor–antibody interaction without
destroying the bioreceptor activity.
It should be possible to automate our developed integrated
microfluidic–BiMW system to perform the complex and repeti-
tive fluid handling required for the competitive assay in order
to detect the presence of tetracycline. Automation of this inte-
grated system should allow a significant increase in assay re-
peatability, while reducing manual labour as well as the influ-
ence of any associated manual error variables.
In these experiments we have employed a tetracycline con-
jugate (DoxAc10-AD) and an antiserum specific for the family
of tetracycline-related antibiotics (As256). The suitability of
this immuno-reagents pair was first tested by a standard Sur-
face Plasmon Resonance (SPR) Biosensor (data not shown),
achieving a LOD of 0.09 nM and an IC50 value of 3.6 nM. The
SPR sensor could be reused for several measure-regeneration
cycles of tetracycline by using 10 mM NaOH solution as a re-
generation buffer.
Surface biofunctionalisation and competitive immunoassay
A previous surface biofunctionalisation of the sensor surface is
mandatory to perform the analysis. In this case we have
employed a silanisation protocol with carboxyethylsilanetriol so-
dium salt (CTES) which provides a surface functionalized with
carboxyl groups, allowing the further covalent immobilisation of
bioreceptors presenting amino groups in their structure, such as
the evaluated hapten–protein conjugate (DoxAc10-AD) by the
well-known EDC/NHS chemistry. Briefly, the BiMW sensors were
first thoroughly cleaned, oxidised (oxygen plasma treatment, 5
min) and immersed in an aqueous 0.5% CTES solution for 1 h.
After that, the CTES-treated chips were rinse with deionised wa-
ter, dried under nitrogen stream and thermally cured at 110 °C
for 1 h. CTES silanisation is performed utilising previously
optimised protocols by our Group.5 The silanised chip is then
aligned with the microfluidic module such that a BiMW sensing
window is located within the sensor channel, and reversibly
bonded. The assembled device is then placed into the experi-
mental setup and connected to the valve driver support equip-
ment (for further information see: Supplementary Material SM-
1:† Experimental setup). Further surface functionalisation steps
are performed utilising the automated microfluidic module, at a
flow rate of 1.5 μL min−1, an automated on-chip fluid handling
protocol is executed with minimal user input, thereby reducing
user introduced variability and resulting in more reproducible
surface conditions. Due to the reactive and time critical nature
of functionalisation reagents, it is necessary to prepare and load
reagents sequentially into on-chip reservoirs as they are
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required. MilliQ DI water is used as a running buffer for the fol-
lowing process: initially, the reactive carboxylic groups of the
silanised sensor surface are activated by flowing 200 mM EDC/
50 mM sulfo-NHS solution in 100 mM MES buffer containing
0.5 M NaCl, at pH 5.0 for 10 minutes. The surface is briefly
cleansed with DI water, followed by flow of the receptor mole-
cule (DoxAc10-AD) at a concentration of 20 μg mL−1 in SA buffer
(pH 5) allowing bonding with the freshly activated surface for 15
minutes. An additional DI water rinse is followed by a final flow
of ethanolamine 1 M (pH 8.5), to deactivate residual carboxylic
groups and to remove electrostatically bound ligand in an effort
to avoid non-specific adsorptions. At this stage the sensor as-
sembly is ready for the competitive assay. In a competitive im-
munoassay different steps are involved. Initially, the sensor sur-
face needs to be conditioned with a buffer solution, until
reaching a stable baseline signal. Then, the sample is mixed
with a constant concentration of the antibody and the mixture
is injected onto the sensor surface, allowing the interaction be-
tween the free antibody and the receptor immobilised onto the
surface. The sensor surface is then washed with buffer to re-
move all unbound material and the signal after stabilisation is
evaluated. Finally, the surface is regenerated and conditioned
again with buffer, starting a new measurement cycle.
The surface functionalisation protocol and the competitive
immunoassay employed are briefly introduced in Fig. 4. Fig. 4A
illustrates the sensor surface in its initial state, 4B–D illustrate
the technique used to immobilise the receptor (DoxAc10-AD)
described above. Fig. 4E illustrates a functionalised surface in
which the receptor molecule has captured the specific anti-
body; following this Fig. 4F shows the target–antibody interac-
tions blocking antibodies from surface interaction.
Automated assay protocol
In order to perform a competitive immunoassay, the auto-
mated system must be able to perform an initial reference as-
say in order to benchmark sensor response to a known anti-
body concentration, followed by a competitive assay which
will be used to quantify the target concentration. This ‘cycle’
of reference and competitive assays are complementary and
must be repeated for each competitive assay. Each assay re-
quires an initial flow of buffer solution in order to achieve a
sensor baseline; this is followed by a sample flow, allowing
surface interaction, likewise followed by a secondary flow of
buffer as a sample washout step. The secondary baseline
attained at washout can then be compared with initial base-
line magnitude to interpret the effect of surface interaction.
The sensor surface finally requires regeneration by actively
stripping the bound antibodies using a mild acid or basic
conditions, and a final buffer flow applied to bring the sys-
tem back to a ready state. Automation of these assay proto-
cols, implemented using the microfluidic module developed
in this work, should result in time consistent cycling of the
required steps of the complex assay, reducing interaction
time variability and ensuring pure sample and reagent deliv-
ery. In order to achieve this, 20 minute detection cycles are
programmed using Python script, automating all fluid han-
dling required to perform an assay and subsequent surface
Fig. 4 Conceptually illustrated surface conditions during surface biofunctionalisation and during a competitive assay. Fig. 4A shows a clean sensor
surface prior to functionalisation, this image represents a cross section of the BiMW, showing the waveguide surface (foreground) at the sensor
window area with the passivation layer seen in green. Fig. 4B illustrates the sensor surface post silanisation with CTES, C illustrates receptor
binding, followed by ethanolamine treatment in D, blocking any unbound carboxylic groups. Fig. 4E illustrates surface interactions during a
reference assay, with antibodies binding to the receptor molecules, while F illustrates a competitive assay, antibody binding sites are occupied by
target molecules reducing overall surface interaction.
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regeneration using the BiMW sensor, with the exception of
sample preparation. Initially running buffer, phosphate buff-
ered saline (PBS) and regeneration fluid (NaOH-10 mM), are
loaded into the on-chip reservoirs. An automated protocol
then primes these channels, sending a small volume through
the waste outlet, ensuring any bubbles are purged from the
system and ensuring reagents are ready at the valve gate
when required. Following initial priming, sample can be
loaded and the automated sequence initiated, this sequence
will initially flush sample through the waste path, cleansing
the system and ensuring that sample delivered to the sensor
is bubble and contaminant free; the sample is then directed
through the sensor channel for 10 minutes passing a total
sample volume of approximately 15 μL, during which time
specific target binding can occur. Following this surface
interaction period, the system flows PBS over the sensor for 4
minutes to flush out any unbound sample and to obtain a
secondary baseline, this is followed by a 3 minute regenera-
tion cycle where NaOH is directed over the sensor surface,
stripping bound antibodies and readying the system for sub-
sequent detection cycles; finally, the sensor surface is washed
out with PBS for an additional 3 minutes returning the sys-
tem to a ready state for subsequent measurements.
This automated protocol performs the assay fluid han-
dling consistently, ensuring that flow conditions and interac-
tion times are consistent for each assay. This was initially ver-
ified through manipulation of colour food dyes in place of
sample and reagent fluids, as shown in Fig. 3C, prior to the
assay application.
Biosensing of tetracycline antibiotic
Application of the automated assay protocol to perform fluid
handling required for the competitive assay should allow re-
peated reproducible assay cycles, allowing target biomarker
quantification, and evaluation of surface chemistry and its effec-
tiveness following multiple regeneration cycles. Prior to experi-
mentation, the sensor was initially biofunctionalised, reagents
loaded into on-chip reservoirs and channels primed using an
automated priming protocol. Then, the response of the sensor
was evaluated by using the automated assay protocol.
As proof of concept, two different samples were analysed:
PBS (sample free of antibiotic, used as a reference sample)
and a 2 nM tetracycline solution in PBS. First, the sample
was mixed with the antibody (AS-256) to a final concentration
of 1 μg mL−1. Then, 15 μL of the sample–antibody mixture
was passed over the sensor over 10 minutes. During this step,
the free antibodies interact with the receptor immobilized
onto the sensor surface. It is expected that the presence of
tetracycline in the sample will result in a lower interaction
signal than the reference (competitive assay). During these
experiments, the reference assay (sample free of tetracycline)
was repeated before each competitive assay (2 nM tetracycline
sample), in an attempt to compensate for degradation of the
sensor surface occurring as a result of repeated surface
regeneration.
Fig. 5 shows the sensor response for a sample free of tetra-
cycline (reference assay) and a sample containing tetracycline
in a concentration of 2 nM (competitive assay), sequentially
analysed. Fig. 5A shows sensor readings during an example
20 minute automated measurement cycle running a target-
free reference sample, with inset (1–4) conceptually illustrat-
ing interactions occurring on the surface of the sensor at var-
ious times during the cycle. The reference sample is mixed
with the antibody and pipetted into the appropriate reservoir
and the automated detection cycle is initiated. Fig. 5B (1–4)
highlights the fluidic path taken from associated reservoirs
at time points corresponding to 5A and 5C. Initially the sen-
sor is immersed in PBS at a constant flow-rate of 1.5 μL
min−1; this is allowed to form a stable baseline, (1) before in-
troduction of the sample. Initially, introduction of the sample
causes a sharp change in signal due to a bulk change in the
refractive index of the spiked sample, this is followed by a
fixed surface interaction period in which antibodies present
in the sample bind to the immobilised receptor, gradually
modifying refractive index at the sensor surface, which can
be seen as a gradual change in the signal and is conceptually
illustrated in (2). Sample washout can be seen as a sharp
change, corresponding in magnitude to that observed at sam-
ple inflow, this is due to the refractive index of the fluid
returning to that of the running buffer or PBS, forming a sec-
ondary baseline, shown conceptually in (3). Finally, the sur-
face of the sensor is stripped of bound antibodies using a re-
generation solution (NaOH,10 mM), this surface regeneration
step (4) prepares the sensor surface for subsequent detection
cycles, following a return to running buffer (PBS) and a re-
turn to the initial baseline (1).
Surface interactions are quantified by assessing the phase
variation of the BiMW interferometer, taking into account
that a complete oscillation or fringe corresponds to a 2π rad
phase variation. The arbitrary sensor signal (%) value, shown
in Fig. 5A and C is tracked from the initial baseline time
point in 5A (1) to the secondary baseline at time point 5A (3),
taking any transitions across the fringe into account and
subtracting the bulk refractive index peak. The total distance
travelled represents the magnitude of the surface interaction
signal, and are shown relative to π inset in Fig. 5A and C.
Fig. 5C displays sensor readings obtained during a competi-
tive assay performed immediately following the reference,
along with corresponding conceptual representations of surface
interactions in insets of Fig. 5C (1–4). The competitive assay is
performed using the same automated protocol as the reference;
however the introduced sample contains 2 nM of tetracycline.
It can be noted that the resultant increase in bulk refractive in-
dex due to additional components present in the sample has
increased the magnitude of the spike observed at sample intro-
duction and washout. It can be seen that the gradient of the
surface interaction shown in area (2), is reduced when com-
pared with the reference sample. It is also clear that the sensor
response (overall magnitude of surface interaction, inset in 5A
and C) is reduced in the competitive assay due to the presence
of the target molecules (tetracycline) in the sample, occupying
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the binding sites of the antibody, thereby reducing the quantity
of available antibodies capable of binding to the receptor in
the surface by an amount proportional to the target concentra-
tion. Fig. 6A overlays the response of a 2 nM tetracycline sam-
ple (competitive assay) and its corresponding reference. As it
can be seen, the presence of 2 nM tetracycline leads to sensor
response of 0.13π rad comparing to 0.28π rad for a sample free
of antibiotic (reference), i.e. the presence of tetracycline lead to
a 54% inhibition of the sensor response. The response of the
competitive assay can be expressed as a percentage of its corre-
sponding reference assay, this is shown in the inset in Fig. 6A,
which corresponds to cycle 2 in Fig. 6B.
In order to assess the stability of the proof-of-concept sur-
face functionalisation, repetitive reference and competitive
cycles were performed, with target and antibody concentra-
tions maintained at constant levels for each repetition.
Fig. 6B illustrates the results, with reference cycles shown in
green and competitive assays shown in red. Raw sensor data
for each assay is shown in Supplementary Fig. S-2.†
As can be observed in Fig. 6B, the sensor response to refer-
ence assays in subsequent pairs reduces significantly. This is
most noticeable between the first two assay pairs, and is pre-
sumably due to degradation of the immobilized receptor dur-
ing the regeneration step. As the presence of target analyte is
Fig. 5 Illustration of the surface interactions occurring at various time points during a reference and competitive assay pair, performed
sequentially. Fig. 5A shows real-time sensor data during an example reference assay, with inset (1–4) conceptually illustrating interactions occurring
on the sensor surface at critical time points during the cycle. Fig. 5B (1–4) highlights the fluidic path taken from the corresponding reservoir at the
same time points during the assay, while Fig. 5C displays sensor readings obtained in a competitive assay performed immediately following the ref-
erence assay, along with corresponding conceptual representations of surface interactions in inset Fig. 5C (1–4).
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detected as response inhibition, this sensor degradation can in-
troduce a false positive result. For this reason, in order to dy-
namically compensate for surface degradation and increase the
lifetime of the biosensor, each competitive assay was directly
preceded by a reference assay. This could be avoided in future
work by optimizing the sensor surface functionalisation proce-
dure (receptor immobilization) and regeneration step. Each as-
say pair was normalized through comparison of the competi-
tive result with its corresponding reference as a percentage,
and the competitive signal in % shown in Fig. 6C.
It can be observed that the response of the sensor to the
presence of tetracycline is comparatively stable, with signals
(sample/reference ratio) at between 40–50% for the initial 4 as-
say pairs, this indicates relative surface stability for
8 measurement-regeneration cycles, with similar stability seen
in repeated assays (data not shown). After 8 analysis a clear
sensor degradation is observed, due to the repeated exposure
of the bioreceptors to the regeneration solution (basic media).
The increase in the competitive signal is presumably due to the
increase in non-specific binding events occurring as surface
degradation results in the biolayer becoming less specific.
This biolayer lifetime is consistent with our previous re-
sults,30 however it is presumable that improvements to the
surface functionalisation protocol used in this proof-of-
concept work could significantly improve surface integrity. In
addition, in order to analyse real clinical or environmental
samples, a more complete development of the biolayer will
be required, adding antifouling properties to prevent non-
specific binding in complex real samples, as we have demon-
strated in previous publications of the BiMW interferometric
biosensor.7,30,32
Conclusion
This work demonstrates a proof-of-concept implementation
of an automated fluid handling module for photonic biosen-
sors. The module is fabricated utilising a one-step injection
moulding technique which significantly reduces fabrication
Fig. 6 Signal interpretation and performance of the proof-of-concept functionalized surface during repetitive regeneration cycles with fixed sam-
ple concentrations. Fig. 6A shows superimposed reference and competitive assay. The presence of tetracycline in the sample leads to an inhibition
of the sensor response. Fig. 6B shows the sensor response for 14 sequential measurement-regeneration cycles, alternating reference sample (free
of antibiotic) and spiked sample (2 nM tetracycline). Fig. 6C shows normalised results with each competitive assay as a percentage of its corre-
sponding reference cycle.
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complexity of normally closed on-chip elastomer valves. This
work makes use of the fabrication technique to realise on-
chip fluid handling architecture required for operation of a
highly sensitive bimodal waveguide photonic biosensor, auto-
mating complex fluid handling protocols required for the op-
eration of a competitive immunoassay.
The capacity of the automated system is demonstrated in a
proof of concept competitive immunoassay for the detection of
the common antibiotic tetracycline. The system is shown to per-
form repetitive automated assay cycles, allowing a high degree of
experimental control and temporal resolution. The system dem-
onstrates multiple reference and competitive assay cycles, reg-
enerating the sensor bioreceptor later between assays, as would
be necessary in real applications requiring periodic testing, such
as in food quality control or environmental monitoring.
This research represents a significant advancement in devel-
opment of practical point-of-care photonic biosensors, provid-
ing complex automated fluid handling capabilities compatible
with simple and scalable fabrication and robust integration.
This research is intended to reduce the cost and effort required
for the fabrication of complex lab-on-a-chip platforms, while in-
creasing the level of functional integration, making application
of these intricate devices across a broad range of research fields
more practical. In addition, a sufficient reduction in fabrication
complexity is intended to enable a higher level of fluidic con-
trol sophistication in point-of-care medical diagnostic devices,
allowing use of more complex biosensors. This research could
potentially be integrated into commercial large scale fabrica-
tion of point-of-care devices.
The automated nature of this system makes it suited to
performing repetitive assay cycles which could be used to
sweep parameters in order to optimise surface chemistry.
Future work will include optimising the biolayer and regen-
eration protocol, with the intention of providing more stable
biosensors and increasing sensor lifetime. Further future work
toward increasing performance when analysing low concentra-
tion targets is planned, including surface passivation similar to
the approaches explored in,40 intended to minimise loss of low
concentration target molecules through non-specific adsorp-
tion in the PDMS module. Further expansion of the system is
intended to allow for multiplexing of multiple biosensors, as
well as the addition of sample preparation subsystems (if re-
quired), providing additional functionality critical to point-of-
care applications. In addition, we intend to exploit the scalabil-
ity of the fabrication technique used in this work through in-
vestigation of other biocompatible elastomer materials compat-
ible with injection moulding, facilitating mass production.
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3.2 –  Label-Free Optofluidic Nanobiosensor Enables Real-Time Analysis of Single-Cell Cytokine 
Secretion 
 
The paper of the previous section focussed on complex microfluidic systems designed to facilitate 
controlled flow and fluidic isolation of various liquid reagents with respect to an underlying 
photonic waveguide-based biosensor.  This sensor operated with the reagents and then the 
analyte flowed over the sensing region during operation. There are however, biosensing 
applications where flow cannot be permitted, where for example a target is required to be 
captured and an assay performed under static and carefully controlled environmental conditions. 
Single cell analysis has shown significant promise in recent years, allowing insight into the 
heterogeneity of various cellular characteristics and response to stimulus, with impact across a 
broad range of fields [47]. Analysis of the secretions of cellular messaging biomarkers, cytokines, 
is one such field, with significant potential in unravelling the mechanism of intercellular 
interactions under various conditions.  
Several challenges exist in maintaining viable cells held isolated in nanolitre scale volumes for long 
duration cytokine secretion analysis. Of primary concern, fluidic isolation of the captured cell is 
necessary to maintain the concentration of secreted biomarkers, however the water content of 
isolated cell culture media can evaporate over time, changing the concentration of dissolved 
components and thus the bulk refractive index, and eventually leading to bubble formation within 
the system. Plasmonic nanohole array biosensors are sensitive label free planar biosensors that 
can provide spatial information on binding of target biomarkers. For this reason, Plasmonic 
nanohole array biosensors are well suited to single cell cytokine detection, allowing observation 
of the spread of target biomarkers from captured cells. These sensors however, are highly sensitive 
to bulk changes in refractive index of the media in which they are sensing, leading to sensor noise 
or false positives, while any bubbles forming in the system are likely to disrupt the sensor. 
While various strategies for controlling gas concentrations have been applied to cell culture 
platforms [48], these systems generally don’t consider vapour transfer within microfluidic systems, 
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or the resulting impact on media refractive index, and such systems have not been applied to 
systems utilising active biosensing elements. 
In the paper of this section, I have developed a microfluidic system consisting of active microvalve 
components, capable of isolating a small volume of fluid around a single cell of interest. The system 
also utilises a regulatory subsystem, which actively maintains the vapor pressure within this 
isolated volume, preventing the minute volume from evaporating, and stabilising the fluidic 
environment around the cell of interest. Microfluidics are fabricated using the injection moulding 
fabrication technique developed in Chapter 2, allowing the fabrication of complex 3-dimensional 
microfluidic components, including active fluid handling components and passive permeable 
membranes, without additional fabrication complexity. 
This work was the result of a collaborative project with the Bionanophotonics Systems Laboratory 
group at EPFL in Lausanne, the system was designed to facilitate robust operation for long duration 
single cell analysis using the plasmonic nanohole array biosensors developed by this group.  
This work Demonstrates that the fabrication method outlined in chapter 2 is practical and well 
suited to the fabrication of complex multilayer microfluidic devices, containing multiple active 
control elements as well as vapour permeable membranes which are particularly important where 
small volumes of fluid must be isolated for long durations.  
 
The work related to this chapter has been peer-reviewed and published in: Small 
This paper was identified as a ‘hot topic’ by the publisher, with a front cover and video abstract as 
seen in the links below: 
The paper can be obtained via the DOI: https://doi.org/10.1002/smll.201800698 [31] 
The front cover can be obtained via the DOI: https://doi.org/10.1002/smll.201870119 [49] 
The video abstract can be seen here: https://www.youtube.com/watch?v=sDjux6M0evw 
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My role in this work was related primarily to the microfluidic component, conceiving the valved 
single cell capture and environmental control components of the system. I was involved in data 
analysis, the formulation of hypothesis based on the effects of the microfluidic environment on 
the biosensor response, and diagnosis of these issues based on biosensor response. I designed 
systems intended to stabilise the biosensor based on these hypothesis, and fabrication of these 
microfluidic systems. I assisted with calculations assessing stability of the microfluidic 
environment, put together several figures for the manuscript and assisted with writing the 
manuscript, focussing on the microfluidic component. As the emphasis of the paper was on 
biomedical application, the two lead authors were the EPFL post-docs who actually conducted the 
single cell analysis, I was the next author as lead platform researcher.  
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epigenomics, and transcriptomics.[2] How-
ever, the analysis of individual cell secre-
tion is essential to fully understand the 
functional heterogeneity and decipher the 
underlying mechanisms of cellular inter-
actions and communication. Intercellular 
signaling and formation of cellular net-
works is a highly dynamic process medi-
ated by the expression and secretion of 
small proteins (e.g., cytokines) and other 
molecules, which identify the particular 
cell activities, behaviors, and functions.[3,4] 
The sensitive monitoring and analysis of 
cell secretion provide invaluable informa-
tion of the specific functionality and real-
time activity of individual cells in either 
physiological or pathological process. 
Such dynamic and accurate analysis is still 
an unresolved challenge. Traditional secre-
tion analysis techniques include enzyme-
linked immunosorbent assay (ELISA) or 
immunofluorescence staining; however, 
these methods lack sufficient sensitivity for detection of single-
cell secretions.[5]
The past few years have seen the advances of innovative 
strategies for both cell isolation and protein secretion anal-
ysis to enable single-cell resolution.[6–9] For instance, Love 
et al. introduced a large-scale microengraved array which 
is able to generate the populational secretion profiles from 
single hybridoma cells,[6] or even to characterize the cytokine 
secretion of single T lymphocytes upon different activation 
scenarios.[9] While their methods are efficient enough to pro-
vide a high-throughput dataset, the intensive washing steps 
involved in the fluorescence labeling procedure dramatically 
impairs the temporal resolution (limited to a few hours) of 
the analysis. On the other hand, droplet microfluidics has 
been presented as a promising platform for single-cell sorting 
and analysis.[10–12] The technique basically involves encapsu-
lating individual cells in droplets loaded with specific fluores-
cent antibodies or enzymes for capturing and detecting the 
secreted cytokines. However, subsequent cytokine quantifica-
tion requires external readout means, such as flow cytometry 
or spectroscopic methods that increase the overall system 
complexity and only provide an end-point result. Despite the 
capabilities of these new techniques for single-cell isolation, 
the need of either fluorescent or enzymatic labels for detection 
significantly impairs the dynamic analysis and monitoring of 
the secretion in real time.
Single-cell analysis of cytokine secretion is essential to understand the 
heterogeneity of cellular functionalities and develop novel therapies for 
multiple diseases. Unraveling the dynamic secretion process at single-
cell resolution reveals the real-time functional status of individual cells. 
Fluorescent and colorimetric-based methodologies require tedious molecular 
labeling that brings inevitable interferences with cell integrity and com-
promises the temporal resolution. An innovative label-free optofluidic 
nanoplasmonic biosensor is introduced for single-cell analysis in real time. The 
nanobiosensor incorporates a novel design of a multifunctional microfluidic 
system with small volume microchamber and regulation channels for reli-
able monitoring of cytokine secretion from individual cells for hours. Different 
interleukin-2 secretion profiles are detected and distinguished from single lym-
phoma cells. The sensor configuration combined with optical spectroscopic 
imaging further allows us to determine the spatial single-cell secretion finger-
prints in real time. This new biosensor system is anticipated to be a powerful 
tool to characterize single-cell signaling for basic and clinical research.
Single Cell Analysis
1. Introduction
Single-cell analysis is one of the most powerful approaches 
toward the development of new therapies for serious dis-
eases such as cancer or autoimmune disorders.[1] The recent 
implementation of advanced analysis technologies (e.g., next-
generation sequencing) has boosted our knowledge and under-
standing of the complex heterogeneity in cellular genomics, 
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Label-free biosensors emerge as a unique solution for the 
sensitive, accurate and real-time analysis of cell secretion.[13–15] 
This detection scheme circumvents the tedious and costly 
molecular tagging and enables the elucidation of biomolecular 
interactions in a noninvasive and dynamic manner. Among 
various label-free sensing platforms, optical biosensors are 
distinguished by their compatibility with physiological solu-
tions, robust performance, and ability to perform quantitative 
detection.[16–20] The recent advances in nanotechnology have 
inspired the development of extraordinarily improved optical 
biosensors based on photonic nanostructures. Nanophotonics, 
by supporting strong light-matter interaction and dramatically 
confining light in small volumes, enables ultralow detection 
limits, exceptional miniaturization, and ultimate on-chip inte-
gration.[21] Particularly, plasmonic nanohole arrays (NHAs) 
have demonstrated a unique potential and flexibility for the 
implementation of powerful biosensors with high-throughput 
analyses and capabilities for point-of-care deployment and uti-
lization.[22,23] Nanohole arrays can be manufactured with cost-
efficient and straightforward techniques,[24] and they overcome 
the primary constraints of conventional surface plasmon reso-
nance (SPR) devices, such as the light coupling requirements 
and the limited field of view for high-throughput assays.[25] Fur-
thermore, gold NHA biosensors have demonstrated exceptional 
performance for the analyses of proteins and cells in a real-time 
and multiplexed label-free configuration.[24,26–28]
However, label-free photonic biosensors face critical chal-
lenges for addressing single-cell secretion analysis. Cytokines 
are relatively small molecules (MW 15–30 kDa) and are 
secreted in minute amounts (femtograms per cell per day). 
Therefore, the direct detection of single-cell secretion in real 
time without any signal amplification is not straightforward. 
In order to achieve the ultrahigh sensitivity required for the 
detection of cytokines secreted from an individual cell, it can 
be effective to minimize the local volume surrounding the cells 
by encapsulating them with microchambers. This will result in 
concentrated molecular distribution in the vicinity of the sensor 
surface. In this regard, microfluidics technology offers a pow-
erful tool to create a highly miniaturized environment with 
compartmentalization for the analysis.[29] Nevertheless, the 
optical monitoring of an ultralow volume in cell culture condi-
tions (i.e., 37 °C) introduces a significant evaporation problem. 
This is especially challenging when using polydimethylsiloxane 
(PDMS) as the material for microfluidics. This widely used 
material provides excellent transparency and high gas perme-
ability, making it an ideal substrate for optical cellular bioas-
says.[30] However, the gas diffusion also leads to evaporation and 
associated optical noise when handling the ultralow volume of 
fluid.[31,32] Water evaporation through PDMS membranes may 
cause not only an increase in osmolality of the cell media but 
may also result in bubble formation and eventually dehydration 
of the cell chamber. These evaporation-mediated osmolality 
alterations induce local changes of the fluid refractive index, 
causing dramatic optical signal fluctuations that overwhelm the 
low magnitude secretion signature of single cells. Conventional 
approaches to prevent liquid evaporation, such as sealing the 
aqueous surface with mineral oil[31] or placing numerous sac-
rificial drops in the vicinity of the analyte chamber,[32] can be 
effective but increase overall system complexity, limit on-chip 
integration and pose potential contaminations to the assay. 
Conversely, thin PDMS membranes between culture areas and 
oxygen equilibrated water channels have been shown to reduce 
evaporation, while at the same time maintaining oxygen levels 
required for sustained culture.[33]
In this work, we introduce a new approach for the single-
cell secretion analysis in real time using a label-free nano-
plasmonic biosensor. We have developed an optofluidic device 
based on a gold nanohole array sensor integrated into an inno-
vative multifunctional microfluidic system for the dynamic and 
accurate monitoring of cytokine secretion from individual cells 
(Figure 1a). The nanohole arrays covering the entire sensor sur-
face are manufactured uniformly with low-cost and wafer-scale 
photolithography. For optical detection, we exploit a spectro-
scopic imaging method which converts each imaged point to an 
effective sensing element. We utilize the single step injection 
molding technique[34] to create a microfluidic system equipped 
with pneumatic valves that enables both the in-flow introduc-
tion of cells into the device and isolation of a microchamber 
Small 2018, 14, 1800698
Figure 1. Illustration of the optofluidic system for real-time single cell analysis. a) Schematic representation of the microfluidic-integrated nanoplas-
monic biosensor. The microfluidic system consists of two fundamental parts: a primary channel in contact with the plasmonic nanohole array chip, 
which includes two pneumatic valve gates for enclosing a small-volume microchamber for single-cell analysis, and a hydraulic regulation channel 
fabricated on top of the microchamber to provide humidity regulation through serpentine water flow. For analysis, the single cells attached to the 
plasmonic chip surface are surrounded by specific antibodies, which will capture the secreted cytokines postactivation. b) The picture of the integrated 
device. We highlight the primary channel (orange) and the regulation channel (blue) with flowing colored dyes, respectively. c) An SEM image of a 
single EL4 cell attached to the nanohole array chip.
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on the nanostructured sensor chip to confine and analyze indi-
vidual cells. A valve-gated microchannel allows us to control the 
flow when introducing the cells that are then isolated within 
a low volume cell chamber, which maintains the cytokine 
concentration at a high level and improves the biodetection 
accuracy. Moreover, we harness the ability of our injection 
molding approach to create a continuous regulation channel 
that interacts with the underlying valve-isolated sub-microliter 
cell chamber through thin PDMS membranes (Figure 1a). The 
regulation flow simultaneously ameliorates evaporation, pre-
vents bubble formation and enables a stable optical background 
signal for robust monitoring of single cell secretion analysis.
Our optofluidic device (Figure 1b) has been applied for the 
label-free detection of interleukin-2 (IL-2) from individual EL4 
lymphoma cells (Figure 1c) in a real-time manner. The secretion 
dynamics can be monitored for a period spanning several hours, 
without any need to disturb the cell culture and label the secreted 
cytokine molecules, while keeping the appropriate temperature 
and humidity conditions for cell activity and viability. The tem-
poral detection interval can be highly customized to ensure suffi-
cient time resolution for the bioanalysis. Furthermore, due to the 
extended arrangement of NHAs over the entire chip surface, we 
have the flexibility to designate multiple detection areas around 
a single cell with varying distances apart, where the cytokine 
diffusion activity can be depicted spatially as well. This versatile 
optofluidic biosensor provides a reliable and facile label-free detec-
tion platform to investigate the onset, dynamics, and diffusion of 
cytokine secretion activities at the single-cell level.
2. Results and Discussions
2.1. Optical Configuration of The NHA Biosensor
The plasmonic nanohole arrays offer highly sensitive label-free 
biosensing and are distinguished among other state-of-the-art 
plasmonic sensors due to the well-proven capabilities for device 
miniaturization, multiplexed analysis, and easy integration in 
lab-on-a-chip devices.[14,22,27] The current fabrication process 
for nanoplasmonic sensors requires sophisticated and costly 
techniques, such as e-beam lithography. This inevitably hinders 
the implementation of nanoplasmonic technology for routine 
biological analysis. Therefore, we have employed a nanofabri-
cation procedure[35] enabling efficient and large-scale produc-
tion of plasmonic NHA chips, which minimizes the costs and 
promotes the real application both in research and clinical 
fields. The fabrication process is based on deep-UV photo-
lithography technique (Figure S1, Supporting Information) by 
using robust quartz wafers as the sensor substrate. As a result, 
we obtained 4-inch diameter wafers (Figure 2a) patterned with 
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Figure 2. Configuration and working principle of the plasmonic nanohole array biosensor. a) The plasmonic nanohole arrays are fabricated uniformly on 
a thin gold film by wafer-scale deep-UV photolithography over the entire 4-inch diameter quartz wafer. b) The nanopatterned wafer is diced to 1 × 1 cm2 
sensor chip for analysis. The appearance of colors on the chip when viewed at a tilt shows the diffraction grating effect resulted from the nanohole arrays 
on its surface. c) An SEM image shows the uniformly distributed nanohole structures on the quartz substrate, where the nanoholes have a diameter of 
200 nm and are separated center-to-center by 600 nm. d) The chip functionalized with biorecognition elements is illuminated normally with a broad-
band light source, exciting the surface plasmons which can be characterized by the appearance of specific EOT resonance peaks in the transmitted 
light. The transmission spectra are recorded and analyzed by the spectroscopic imaging setup, forming spectral images over time from t0 to tn. The 
two axes of the spectral images correspond to spatial position and wavelength. Upon analyte binding to the biorecognition elements, the change of 
refractive index on the plasmonic surface induces a wavelength shift of the resonance peak of the transmitted light. e) The spectral wavelength shift 
of the EOT resonance peak extracted from the spectroscopic images can be quantified directly in proportion to the changes of refractive index due to 
accumulated mass on the nanohole array surface. f) A sensorgram is obtained by tracking the resonance shift in real time, enabling the monitoring of 
biomolecular binding in a label-free manner.
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uniform arrays of gold nanoholes (200 nm diameter, 600 nm 
period) across the entire wafer surface as confirmed by SEM 
image analysis (Figure 2c). Wafers were further diced into 
small sensor chips of 1 × 1 cm2 (Figure 2b) for cell analysis. 
The working principle of this biosensor is based on the phe-
nomenon of extraordinary optical transmission (EOT), which 
is represented as a dramatic enhancement of light transmis-
sion through the regularly periodic subwavelength nanohole 
structures.[36,37] This light enhancement is characterized by the 
appearance of an EOT resonance peak in the transmission spec-
trum. The EOT resonance is highly sensitive to minute changes 
in the near-field refractive index over the nanohole surface. 
The molecular binding on the sensor surface induces a varia-
tion of the refractive index that leads to a spectral shift of the 
peak wavelength (Figure 2d). By tracing the spectral shifts with 
ongoing experiment time, we are able to depict the molecule 
binding events in a real-time format.
We characterized the performance and sensitivity of our 
NHA biosensor for label-free spectroscopic imaging. For the 
measurements, we placed the sensor chip on an inverted 
microscope where a collimated broadband light source illumi-
nated the NHAs at normal incidence, resulting in the onset 
of EOT phenomenon (Figure S2, Supporting Information).[38] 
The transmitted light was collected by the objective under-
neath and coupled to a spectrometer through a 500 µm wide 
slit opening. The spectral content is then dispersed by a grating 
(600 lines mm−1) and recorded on a 1024 × 1024 pixel CCD 
camera with a pixel size of 13 × 13 µm2. The recorded CCD 
image consists of a spatially resolved 1D spectral image in 
which the horizontal axis represents the range of optical wave-
length while the other represents the positions across the illu-
minated area of the NHAs through the slit opening (Figure 2d). 
By adjusting the wavelength to the EOT resonance position (i.e., 
≈860 nm in aqueous solution), we can directly observe the EOT 
peak (Figure 2e) and monitor the spectral displacements in real 
time (Figure 2f). To evaluate the system sensitivity, we carried 
out a bulk refractive index calibration, which was determined 
to be 630 nm RIU−1 (Figure S2, Supporting Information). This 
sensitivity outranges the majority of the state-of-the-art nano-
plasmonic biosensors, demonstrating the unique potential of 
our system to perform single-cell secretion analysis.[21,39,40]
2.2. Surface Functionalization of NHA Biosensor for Cell  
Capture and Cytokine Detection
The establishment of a robust and stable surface chemistry 
strategy is critical in affinity-based biosensors to ensure sen-
sitive, selective and reliable biodetection of the analytes-of-
interest from a complex matrix such as cell media. This is 
particularly essential for in situ single-cell analysis since we 
ought to coimmobilize both cell and cytokine capturing probes 
(i.e., antibodies) for an extended period of time. Figure 3a illus-
trates the schematics of the designed surface functionalization. 
First, we coated the gold chip surface with an antifouling self-
assembled monolayer (SAM) composed of polyethylene glycol 
(PEG) derived compounds, preventing binding of nonspecific 
molecules.[41] In particular, a mixture of two kinds of PEGylated 
alkanethiols was employed, with one carrying a reactive 
carboxylic functional group (COOH) and the other 
nonreactive hydroxyl group (OH), respectively. The latter 
serves as a lateral spacer to minimize steric hindrance effects 
during protein attachment. The reactive carboxylic groups were 
subsequently activated by the general carbodiimide chemistry 
(i.e., EDC/NHS activation) that allows covalent binding of 
molecules presenting terminal amine groups (NH2). At this 
point, we coimmobilized a mixture of streptavidin and poly- 
L-lysine (PLL), both containing a significant amount of terminal 
amine groups. PLL is a well-known polymer with the positive net 
charge that acts as an electrostatic force to attach floating cells 
(negative net charge),[42] avoiding any chemical modification 
of the cell membrane and therefore ensuring immobilization 
without affecting the cell physiology. Streptavidin was in turn 
used for the highly stable and oriented immobilization of bioti-
nylated antibodies (Ab) against the cytokine of interest (IL-2). 
We tested the efficacy of our surface chemistry strategy for both 
cell attachment and cytokine detection, by depositing a cell sus-
pension sample on the functionalized chip and incubating for 
1 h at 37 °C. After carefully rinsing, we confirmed the presence 
of cells immobilized on the NHA surface by scanning electron 
microscopy (Figure 1c).
To evaluate the biosensor sensitivity for cytokine detection, 
we performed a calibration curve with standard protein sam-
ples. Samples spiked with different concentrations of recom-
binant IL-2 proteins (from 50–1000 pg mL−1) were introduced 
over the functionalized NHAs. We employed a conventional 
PDMS microfluidic system with microchannels (500 µm wide, 
180 µm high) for the sample injection, which was connected 
to a syringe pump for a continuous buffer flow. As shown in 
Figure 3b, the capturing of IL-2 to the antibodies was depicted 
by resonance shifting (Δλ) in a concentration-dependent 
manner. Higher concentrations of IL-2 samples lead to a 
greater resonance shift, as well as the progression of signals 
being accelerated with increasing concentrations. The plateau 
Δλ values obtained from each sample were then plotted as 
a function of the corresponding concentrations. By fitting to 
a nonlinear regression model (Figure 3c), we determined the 
limit of detection (LOD) of our biosensor, which is defined 
as the concentration with a signal amplitude corresponding 
to three times the standard deviation of the blank signal.[43] 
Based on the background signal we obtained from the zero-
spiked sample, we achieved an outstanding LOD of 39 pg mL−1 
(2.6 pM) for IL-2 detection.
2.3. Design and Characterization of the Multifunctional  
Microfluidic System
Renewal of continuous media flow as employed in conventional 
microfluidic cell assays is not practical for single cell analysis, as 
it inhibits the accumulation of cell secretions, and thus results 
in depletion of target molecules. Isolating target cells within an 
enclosed volume, and minimizing this incubation chamber size 
would naturally facilitate sensitive biodetection required for 
single-cell resolution, through minimization of diffusive target 
loss. However, a number of challenges emerge. The intrinsic 
property of high gas permeability of thin PDMS membranes 
enables this material to be ideal for live cell culture. However, 
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this permeability also leads to evaporation of water through 
the PDMS structure, which can be problematic for long-term 
experiments. The significant degree of evaporation and subse-
quent shift in refractive index hampers the nominal operation 
of the NHA biosensor (Figure 4a).
We experimentally verified the detrimental effects of flu-
idic evaporation through bulk PDMS on sensor reliability with 
a basic microfluidic channel design placed within a 37 °C envi-
ronment (Figure 4b). The evaporation induced significant drift 
in the resonance response compared to room temperature with 
the same relative humidity and under the same illumination 
scheme. Whereas, we obtained a more stable optical readout 
by supplying doubled humidity surrounding the microfluidics 
placed in a custom humidity box. This experiment confirmed 
Small 2018, 14, 1800698
Figure 3. Surface chemistry and characterization of the NHA biosensor for IL-2 detection. a) Surface functionalization strategy for cell attachment and 
in situ detection of secreted cytokines: the gold surface is modified with a PEGylated alkanethiol self-assembled monolayer (SAM), functional groups 
of the SAM (COOH) are activated to bind to a mixture of streptavidin and poly-L-lysine covalently. Streptavidin is used to firmly attach the biotinylated 
antibodies against the target cytokines, while poly-L-lysine to stabilize the anchoring the cells on the sensor surface. b) Real-time sensorgrams of dif-
ferent concentration of cytokines (IL-2) ranging from 50 pg mL−1 to 1 ng mL−1. c) Standard calibration curve for direct and label-free detection of IL-2 
molecules. Each data point represents the mean value of 3 replicates. The limit of detection (LOD) is determined as the signal corresponding to three 
times the standard deviation of the blank.
Figure 4. Design and characterization of the microfluidic system. a) Schematic illustration representing the evaporation of water from the PDMS 
microchamber (RHin) to the surroundings (RHout). b) Baseline drifts of the resonance peak under different conditions surrounding the microchamber 
with varying temperature and relative humidity. c) Schematic representation of the microfluidic system design with the primary channel for cell injec-
tion and culture (pink), pneumatic actuation (white) and the regulation channel blue). Zoom-in figures represent the cross-sectional view of the 
microfluidic system and the valve actuation mechanism. Real pictures of the microfluidic system are shown at the bottom. d) Numerical calculations 
of the vapor loss dependency on the temperature at different relative humidity. e) Numerical calculations of the vapor loss dependency on the relative 
humidity at 37 °C. f) Schematic illustration representing the compensation for the evaporation by the regulation channel filled with water. g) Baseline 
drift comparison of the sensor signal obtained without regulation (red) and with the regulation system (green) filled with water (100% humidity).
1800698 (6 of 11)
www.advancedsciencenews.com
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-journal.com
that relatively high humidity is crucial to prevent evaporation 
and therefore to facilitate stable optical measurements.
In order to stabilize optical response under cell culture con-
ditions, we have designed a novel multilayered microfluidic 
system utilizing our recently introduced injection molding fab-
rication technique (Figure S3, Supporting Information).[34] This 
system allows an isolated microchamber (Length × Width × 
Height ≈ 2 mm × 500 µm × 180 µm) with a chamber volume 
of 180 nL for cell measurements while compensating for vapor 
loss across the gas permeable PDMS structure. The micro-
fluidic device utilises normally closed pneumatically actuated 
microvalves to isolate the fluid within the small incubation 
chamber. A schematic of this system is shown in Figure 4c. 
The primary channel is fabricated in the bottom layer for 
simple introduction of cells to the biosensor and potential 
cell retrieval after analysis. The upper layer incorporates the 
pneumatic lines and actuation chambers required to actuate 
the isolating microvalves, and a serpentine hydraulic regula-
tion channel to regulate the local humidity and temperature 
of the incubation chamber. This is facilitated through a thin 
PDMS membrane present between the regulation and primary 
channel.
Evaporation of water occurs due to the vapor pressure differ-
ence across the wet and dry sides of a PDMS membrane. Based 
on the theoretical evaluation (Supporting Information 1.3), the 
evaporation rate through a PDMS membrane would mainly 
depend on the surface area and thickness of the membrane as 
well as the temperature and relative humidity of the ambient 
environment. Using this equation, we calculated the evapora-
tion rate versus different environmental parameters, particu-
larly the typical cell culture temperature (i.e., 37 °C). As shown 
in Figure 4d, increasing temperature promotes evaporation. In 
contrast, elevating the relative humidity on the wet membrane 
minimizes the evaporation from the incubation chamber, and 
ultimately reduces to nearly zero at a relative humidity of 100% 
(Figure 4e), which corresponds to the conditions when the 
regulation channel is filled with water, as shown in Figure 4f. 
At this point, although the vapor loss through the bulk PDMS 
and dry membranes persist, it is compensated by vapor transfer 
across the wet membrane driven by resulting vapor pressure 
difference. This is evidenced by the improved stability of the 
signals shown in Figure 4g.
2.4. Real-Time Analysis of IL-2 Secretion from Single EL4 Cells
After characterization and optimization of our optofluidic bio-
sensor, we examined the performance for direct and label-free 
single cell IL-2 secretion analysis. IL-2 is one of the essential 
cytokines that are actively involved in numerous biological 
activities of the immune system, and it particularly exerts 
prominent functions in regulating the proliferation, activa-
tion, and differentiation of T lymphocytes.[44] Therefore, the 
dynamic analysis of IL-2 secretion events provides insights to 
better understand its pathophysiological roles in the immune 
system as well as its potential applications in disease treat-
ments. We selected EL4 lymphoma cells for our experiments, 
as these cells are engineered to secrete IL-2 cytokines only upon 
defined chemical stimulus,[45] which represent an optimum 
IL-2 secretion cell population to evaluate the sensitivity and 
specificity of our new analytical platform.
To perform the assay, we functionalized the nanoplasmonic 
chip as described before and assembled it with the multilayer 
microfluidic system. EL4 cells suspended in cell media were 
introduced into the primary channel with an ultralow cell den-
sity. The pneumatic valves were subsequently closed to stop the 
flow which resulted in a few isolated single cells being enclosed 
in the valve-gated chamber (Figure 5a). After a short period of 
incubation at 37 °C to allow firm cell attachment to the NHA 
surface, the optofluidic device was placed in the inverted micro-
scope equipped with a customized incubator box that provides 
the proper temperature and CO2 to maintain appropriate cell 
Small 2018, 14, 1800698
Figure 5. Real-time spectroscopic imaging of single-cell secretion. 
a) Optical images of an isolated cell encapsulated in the microfluidic 
chamber. b) CCD image of a single cell positioned in the center of the 
partially closed slit in the spectrometer. We cropped the image to high-
light the attached single cell. Scale bar: 25 µm. c) The 1D spectroscopic 
image shows the EOT peak intensifies around 865 nm (red region) and 
the spectral signature generated by the cell spot. The region of interest 
(ROI, boxed with dashed line) for measurement is defined around the cell 
spot. d) Real-time sensorgrams obtained from a single EL4 cell secreting 
IL-2 cytokine upon chemical stimulation (black) and a negative control 
without the stimulus (gray). Inset figures schematically illustrate the IL-2 
secretion and in situ capture by co-immobilized antibodies.
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culture conditions. Afterward, a collimated beam of broadband 
light illuminated the assembled device at normal incidence. 
We used a 20× magnification objective to image a single EL4 
cell. The transmitted light through the NHAs entered the par-
tially open slit in the spectrometer, forming an optical image 
recorded by the CCD camera as shown in Figure 5b. For illus-
tration purpose, the acquired image was cropped to highlight 
the location of the cell. By further expanding the recorded 
image across the wavelength range, we obtained a 1D spectro-
scopic image (Figure 5c), where the spectral information was 
revealed alongside the exposed region of the NHAs through 
the slit. An evident signature in the spectrum appeared at the 
exact location where the single EL4 cell resides, which resulted 
from the distinct refractive index of cells. This unique phenom-
enon allowed us to position a single cell during spectroscopic 
imaging and define a specific region of interest (ROI) for bio-
detection. The ROI was subsequently defined in a way that it 
covers the cell position and the immediate surrounding NHA 
areas functionalized with anti-IL2 antibodies. In particular, we 
designated a 40-pixel ROI which corresponds to ≈30 µm on the 
NHA surface. Then, we extracted the corresponding spectrum 
of the transmitted light, which shows the EOT resonance peak 
at ≈860 nm. In order to monitor the capture of analytes in real 
time, we developed customized MATLAB scripts based on the 
centroid algorithm[26] to continuously interrogate the resonance 
peak shifts and to provide a precisely recorded sensorgram. 
Rather than simply tracking the shifts of maximum peak value, 
we significantly enhance the signal-to-noise ratio and improve 
the biosensor sensitivity. We exploited a custom built MATLAB 
interface that allows ROI definition, spectrum visualizing, cen-
troid calculation and real-time sensorgram display in a user-
friendly manner.
To start the analysis, we injected the chemical stimulus 
including the Ca2+ ionophore ionomycin and the phorbol 
ester PMA into the primary channel to initiate the activation 
and secretion of the EL4 cell. Immediately following stimula-
tion, we closed the valve gates to keep a static and controlled 
volume in the cell microchamber. Then, we commenced the 
continuous monitoring of the peak position that displays the 
sensorgram in real time (t = 0). As shown in Figure 5d, we 
observed a significant resonance shift emerging at around 
t = 110 min (black curve). The signal increase could be 
directly attributed to the secretion and in situ capture of 
the IL-2 molecules. We performed an independent negative 
control experiment employing the same cell culture envi-
ronment and analysis conditions but without injecting any 
external stimuli to verify this phenomenon. EL4 cells are a 
well-characterized cell line that only secretes IL-2 proteins 
upon proper activation by the chemical stimulus, so cells 
in common culture media should not produce any sensor 
response. As can be seen in Figure 5d, the gray line remained 
stable over the whole analysis duration. The absence of reso-
nance response from the negative control indicates that our 
biosensor is not only selective for the detection of IL-2 but 
also repellent to other matrix proteins present in the culture 
media, avoiding any interference with the cell analysis. We 
demonstrated that our innovative lab-on-a-chip system is 
able to detect protein secretion from a single cell in a precise 
and accurate manner.
2.5. Temporal and Spatial Diffusion Analysis of Single-Cell 
Secretion
To account for the detection flexibility of our NHA sensing 
surface, we further exploited the biosensor to characterize 
the spatial features of single cell secretion in real time. The 
design of our nanoplasmonic surface with a uniform surface-
spanning NHAs enables the simultaneous and independent 
monitoring of different ROIs. This feature permits not only 
analysis and detection of single-cell secretion in real time, 
but observation of the molecular diffusion along the sensor 
surface. Following the same procedure described before, we 
introduced different EL4 cells in the biosensor and enclosed 
them in the microfluidic chamber. Figure 6a shows the spec-
tral signature of an isolated cell attached to the NHA chip, 
and enclosed within the valve-gated PDMS microchamber. In 
order to analyze the spatial diffusion of the secreted cytokines, 
we defined different ROIs covering the specific cell spot and 
surrounding areas (Figure 6b). In this case, each ROI meas-
ures 20 pixels in width and separates 40 pixels (center-to-
center) away from each counterpart. Considering the overall 
optical magnification of the system, each ROI was ≈13 µm 
in width and ≈27 µm in period. The ROIs were extracted as 
independent spectral curves, and the peak centroids were 
interrogated in real time (Figure 6c).
We performed this measurement for three independent 
single EL4 cells (Figure 6d–f). In all cases, we observed a burst 
of IL-2 secretion at around 110–120 min poststimulation from 
the cell spot, as well as from the adjacent ROIs (ROI 1 and 1’). 
There was roughly 20 min of delay for the onset of resonance 
response from ROI 2/2’. The amount of resonance shifts 
declined from the cell spot outward, which we attribute to the 
diffusion process of cytokines in the static media environment. 
By plotting the endpoint secretion amount of IL-2 (in this 
case, at 180 min) as a function of different ROIs’ locations, 
we obtained a bell-shaped secretion distribution (Figure 6g–i), 
where the secretion apex occurred within the central cell spot 
and declined almost symmetrically outward. It should be men-
tioned that the label-free biosensing configuration is not able 
to provide a 3D mapping of the cytokine secretion around 
the cell, but only the spatial distribution along the sensor sur-
face surrounding the cell. However, the absence of flow in the 
microchamber and the long-time monitoring might facilitate 
the secreted cytokines to diffuse effectively across the sensor 
surface and therefore enable the quantification. The local IL-2 
concentration was calculated by interpolating the relative reso-
nance shift to the calibration curve (Figure 3c). We found sig-
nificant differences among the three different cells. Especially 
the second measurement (Cell 2) showed a higher amount of 
secreted IL-2 (2500 pg mL−1) while Cell 1 and Cell 3 appear to 
secrete less cytokine. This was also reflected in the spatial dif-
fusion analysis, where we observed a more centralized spatial 
distribution for Cell 2. This phenomenon reveals the intrinsic 
heterogeneity in a bulk cell population. Whereas by using con-
ventional methods for cell secretion analysis (e.g., ELISA), we 
would only obtain a single average value for IL-2 secretion at 
discrete time points. Our single-cell analysis method is prom-
ising for accurate observation and precise measurement of pro-
tein secretion from individual cells.
Small 2018, 14, 1800698
1800698 (8 of 11)
www.advancedsciencenews.com
© 2018 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.small-journal.com
It is worth emphasizing that some stochastic noise was 
observed at the cell spots for Cell 1 and Cell 2 while leaving 
other ROIs clear of such interference (Figure 6d,e). We could 
attribute this noise to either cell membrane changes or sto-
chastic cellular movement.[46] In order to prove this hypothesis, 
we performed another experiment where we split the trans-
mitted light beam to simultaneously image the cell with a CCD 
camera and measure the plasmonic response. We observed the 
cell movement within an extremely narrow margin (less than 
10 µm) before the onset of cytokine secretion (Figure S4, Sup-
porting Information). This confirms that during the early stage 
of cell activation, cells undergo certain movements and possible 
membrane activities. The narrow scope of activity does not 
influence the detection of cytokines in the surrounding areas. 
It is important to mention that such phenomena were absent 
for Cell 3 measurement, while this cell secreted a much lower 
quantity of cytokines compared to the others. Therefore, the 
active cell movements could be associated with a higher secre-
tion capacity. Overall, we have demonstrated the superior capa-
bilities of our innovative optofluidic system for the single-cell 
analysis. This microfluidic-integrated nanoplasmonic biosensor 
enables a complete analysis of cell activation and secretion 
from isolated individual cells in a label-free, real-time, and user-
friendly manner. By expanding the real-time single-cell analysis 
to a high-throughput configuration with the incorporation of 
microfluidic cell traps or other strategies,[47] we would be able 
to identify and study cell activation and secretion more effi-
ciently. Besides, the possibility of retrieving the cells after the 
analysis would make our optofluidic sensor an ideal system for 
its application in biomedical research.
3. Conclusion
We introduce a novel design of an optofluidic nanoplasmonic 
biosensor for single-cell cytokine secretion analysis. This bio-
sensor platform builds upon the ultrasensitive gold nanohole 
arrays integrated with an easy to fabricate but sophisticated 
microfluidic system, enabling real-time monitoring of pro-
tein secretion from live cultured cells at single-cell resolution 
in a label-free manner. The integration of pneumatically actu-
ated valve gates in the microfluidic device generates an iso-
lated chamber with a few nanoliters volume for sensitive cell 
analysis. In particular, we incorporate for the first time a novel 
Small 2018, 14, 1800698
Figure 6. Temporal and spatial diffusion analysis of single cells by label-free spectroscopic imaging. a) Spectral CCD image of the optofluidic system 
with three isolated cells encapsulated in the microchamber. Strong spectral gaps correspond to the interfacing PDMS of the regulation channel. 
b) Zoom-in of the spectral image for the ROIs definition at the center cell spot and surrounding areas. c) Spectral EOT peaks corresponding to the 
selected multiple ROIs. The peaks are interrogated simultaneously and independently. d–f) Independent measurements of IL-2 secretion from three 
different EL4 cells, monitoring the cell spot ROI and surrounding ROIs simultaneously. g–i) Spatial diffusion analysis of the secreted cytokines: plots 
correspond to the interpolated concentration of signals acquired for every ROI, fitted to a Gaussian distribution.
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multifunctional microfluidic design involving both regulation 
and primary microchannels to tackle the common PDMS-
mediated evaporation challenge for reliable biodetection. This 
novel design circumvents the need for conventional oil sealing 
or providing a rather high ambient relative humidity, achieving 
a user-friendly and facile biodetection configuration. With this 
biosensor setup, we achieved an outstanding sensitivity of 
39 pg mL−1 for direct IL-2 detection in complex media. The 
IL-2 molecules secreted from individual EL4 lymphoma cells 
can also be directly monitored over several hours without inter-
rupting the cell culture. The uniform arrangement of NHAs 
over the whole sensor chip surface also allows us to elucidate 
the spatial distribution of cell secretion. Furthermore, the 
analysis with different single EL4 cells reveals distinct finger-
prints for secretion capacity despite their similar phenotypes. 
With these capabilities, the proposed nanoplasmonic biosensor 
system represents a powerful tool to analyze cytokine secretion 
at the single-cell level in a label-free and real-time manner.
4. Experimental Section
Fabrication of NHA-Based Biosensor: The gold NHA chips were 
manufactured by using wafer-scale and high-throughput nanofabrication 
techniques on a robust, transparent quartz substrate in a single 
lithography step. Briefly, Radio Corporation of America (RCA) cleaned 
4 inch fused silica wafers were first coated with Ti/Au (10/120 nm) by an 
e-beam evaporator (Alliance-Concept EVA 760). The Ti layer enabled the 
Au adhesion on the glass substrate, as well as suppressed the irrelevant 
surface modes induced by the Au/glass interface. Therefore, only the 
(1, 0) Au/Medium EOT peak could be monitored through a wide 
spectral interval, which was critical for wide dynamic sensing range. 
Next, the NHAs (200 nm diameter and 600 nm period) were patterned 
using a 248 nm deep-UV stepper (ASML PAS 5500/300 DUV) and were 
transferred into the Ti/Au layer using an ion beam etching tool (Oxford 
Instruments PlasmaLab 300 IBE) after developing the photoresist. The 
resist residuals on the surface were removed by oxygen plasma cleaning. 
Finally, the 4 inch processed wafer was diced into 1 cm × 1 cm chips for 
the subsequent optical measurements.
Fabrication of Microfluidic System: Microfluidic devices were 
manufactured with polydimethylsiloxane (PDMS, SYLGARD 
184 SILICONE ELASTOMER KIT) by using a combination of the 
membrane sandwich fabrication method[48] and PDMS injection 
molding technique.[34] Figure S3 (Supporting Information) illustrates 
a pair of complementary molds that were utilized for the injection 
molding process. Molds were fabricated by standard photolithography 
techniques,[49] as described in the previous work.[34] In brief, SU-8 
3050 (MicroChem Corp) was used to pattern the transparent upper 
borosilicate glass wafer substrate, and lower silicon wafer substrate 
with protruding features, with a height of 160 and 180 µm, respectively. 
PDMS prepolymer was prepared by mixing the silicone elastomer 
and the curing agent with a weight ratio of 10:1 respectively, followed 
by thorough degassing in a vacuum desiccator. The prepolymer was 
introduced between the molds, which were optically aligned and 
clamped in position under a dissecting microscope. Standoff distance 
between the molds could be adjusted by changing the spacer material 
positioned between supporting pillars regularly positioned across the 
molds. The clamped mold assembly was cured in an oven at 80 °C for 
1 h and separated to extract the cured PDMS slab, which was further cut 
to size and biopsy punched with viaducts providing a pathway between 
the primary channel and primary channel interface lines. The upper 
surface was plasma bonded (Harrick Plasma PDC-002: 100% O2, 1 min) 
to a 5 mm thick blank PDMS interface slab that was previously biopsy 
punched with 1 mm interface holes aligning with the interface areas on 
the fluidic inlets, outlets, and pneumatic interface areas. Microchannels 
were patterned on both sides of the injection molded slab, namely, 
the primary channel measuring 500 µm in width for cell culture on the 
bottom surface, which corresponds to 500 µm wide fluidic interface 
lines on the upper surface, pneumatic actuation channels and 300 µm 
wide fluidic regulation channels were also patterned on the upper layer. 
The fluidic interface lines connected through biopsy-punched viaducts 
to the accessible interface areas, allowing fluidic access to the primary 
channel on the bottom layer. The complementary molds were separated 
by ≈60 µm during PDMS casting, resulting in a thin PDMS membrane 
(i.e., the regulation membrane) between the regulation and the primary 
channels. The detailed fabrication process of the pneumatically 
controlled valves was described elsewhere in a previous work outlining 
the simplified method by injection molding.[34] In Brief, the valve gates 
consisted of protruding barriers obstructing fluid flow positioned within 
the primary channel, directly under the actuation chambers, and forming 
an isolated channel segment as the incubation chamber. A thin PDMS 
membrane separated the hexagonal pneumatic actuation chambers and 
primary channel. When the actuation chambers were evacuated, the 
valve membranes were deflected upward, raising the valve gates clear 
of the primary channel floor and allowing fluid flow across the valves. 
The regulation channel passed in parallel above the primary channel and 
followed a serpentine configuration directly over the valve-gated area, 
readily maintaining the steady state of the isolated volume underneath 
the membrane.
Functionalization and Characterization of the Biosensor for IL-2 
Detection: The nanoplasmonic chip was cleaned by consecutive washes 
in acetone, ethanol, and Milli-Q water, and then further treated with a 
UV-ozone cleaner (Bioforce Nanosciences) for 20 min. The detailed 
functionalization procedure is described in our previous publication.[25] 
Briefly, the cleaned chip was first coated with a mixture of PEGylated 
alkanethiols in absolute ethanol overnight at room temperature. The 
carboxylic groups on the chip surface were then activated by incubating 
with a cross-linking solution containing 200 × 10−3 m EDC and 
50 × 10−3 m sulfo-NHS in 0.1 m MES buffer (pH = 4.5) for 15 min at room 
temperature. Subsequently, the activated chip was incubated with 0.01% 
poly-L-lysine and 100 µg mL−1 streptavidin solution diluted in phosphate-
buffered saline (PBS) overnight at 4 °C, followed by incubation with 
biotinylated IL-2 antibodies (50 µg mL−1) at room temperature for 1 h.
To determine the bulk refractive index sensitivity, a serial sequence 
of incrementally increasing dilutions of glycerol solutions with known 
refractive indices (RI)[50] was introduced in the biosensor and tracked 
the induced the resonance shifts (Figure S2, Supporting Information). 
By plotting the resulting wavelength changes (Δλ) and fitting to a linear 
regression equation, the bulk sensitivity of the sensor (i.e., slope) was 
determined to be 630 nm RIU−1 (Figure S2, Supporting Information).
To calibrate the optical responses to multiple concentrations of IL-2, 
the standard recombinant IL-2 proteins diluted in PBS with gradient 
concentrations were injected over the biosensor chip at a flow rate 
of 20 µL min−1. We utilized a conventional microfluidic system with 
microchannels (500 µm wide, 180 µm high) for the sample injection, 
which was connected to a syringe pump for continuous buffer flow. 
Each concentration was measured in triplicate. The chip surface could 
be regenerated by injecting 20 × 10−3 m NaOH solution post each 
injection. In addition, the calibration curve does not differ significantly 
from different dilution medium (i.e., cell medium vs PBS), which 
excludes possible matrix interferences. The limit of detection (LOD) of 
the biosensor was defined as LOD = 3 × σx, where σx is the standard 
deviation of the background optical signal.
Optical Measurement Setup and Data Processing: A spectrometer 
(Shamrock 303i, Andor, spectral resolution 0.1 nm) and a deep-cooled 
CCD camera (iKon-M, Andor) were installed onto an inverted microscope 
(Nikon Ti-U) to perform EOT-based optical measurements. A broadband 
tungsten–halogen lamp illuminated the nanoplasmonic chip at normal 
incidence. For single cell monitoring, the EOT signals were collected 
using a 20 × objective (CFI Plan Fluor DLL, NA = 0.5) lens from one 
individual EL4 cell and entered the spectrometer through a 400 µm wide 
slit opening, forming a 1D spectroscopic image. Andor Solis software 
was employed to analyze the spectra. Due to the spatial coverage of the 
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nanostructures over the entire sensor surface, it was flexible to define 
the measurement loci according to specific needs, namely by selecting 
different positions of the region-of-interest (ROI). The spectroscopic 
images were obtained with 0.5 s exposure, and a grating of 600 lines 
mm−1 was used to have sufficient spectral resolution. The spectra 
were extracted from each ROI on the image by a custom MATLAB 
image processing script. The resonance peak position was defined by 
calculating the centroid of the peak within a fixed wavelength window 
(40% maximum intensity) and plotted in real time. Sensorgrams showed 
the centroid shifting versus time of multiple ROIs simultaneously. To 
extract reliable information from cell secretion, the sensorgrams were 
further normalized employing a control ROI placed on a cell-free region. 
To quantify the spectral shift and interpolate the calibration curve, curve 
fitting of the sensorgrams was performed with nonlinear regression 
using GraphPad Prism 7. The correlation between cytokine diffusion and 
multiple ROI locations was analyzed by Gaussian Lorentizian distribution.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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CHAPTER 4: Hemocompatible complex microfluidics for clinical blood analysis 
 
The overall aim of this thesis is to explore whether simplifying the fabrication approach for 
complex microfluidics can reduce the barrier for uptake of this technology and advance it towards 
reaching the potential of mass deployment.  Chapter 2 introduced a simplified fabrication 
technique and Chapter 3 showed that the technique could greatly accelerate the development of 
complex microfluidic components for research applications. In Chapter 3, complex microfluidic 
control components were used to manipulate basic, pre-prepared biological sample fluids used in 
an automated assay, as well as more complex samples including live cells. While basic pre-
processed biological samples don’t require strict adherence to carefully controlled environmental 
conditions, more complex samples containing viable cell cultures are sensitive to environmental 
conditions including temperature, humidity, dissolved gas and nutrient concentrations, fluid PH 
and more [50].  With this said, the environment generated and maintained in Section 3.2 was 
somewhat idealised as is often the case for laboratory research.  
In real world clinical diagnostics, the sample of interest is often derived from blood.  Blood is an 
exceedingly complex biological fluid, a vast amount of information can be extracted through 
analysis of biomarkers present within blood plasma [51], as well as direct analysis of various 
cellular components and their response to stimulus [52]. While blood or its constituents contain a 
wealth of valuable targets for a broad range of assays, there are numerous challenges associated 
with handling of blood in an in-vitro environment. While the influence of the above parameters 
can affect blood with a relationship dependant on exposure time, various blood components are 
sensitive to flow conditions, surface contact, and mechanical stimulation resulting from fluid 
manipulation at very short or transient timeframes, particularly whole blood containing platelets 
[52].  
For these reasons, blood samples are usually processed and divided into their constituent 
elements using macro scale tools in a clinic such as centrifuge and filter columns among others.  
These require a well-equipped clinical laboratory and skilled operators and can take significant 
time and require relatively large quantities of blood.   
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It would be a great advantage to devise lab-on-a-chip solutions that could take whole blood 
sourced directly from the patient as a sample input, removing the need for sending the sample to 
a specialised laboratory, reducing the wait time and requiring minute sample volumes.  For this 
reason, automation of fluid handling and sample preparation using whole blood as the sample 
fluid, has the potential for breakthrough impact in point-of-care applications of numerous 
biosensor strategies. 
Microvalves are a critical control component enabling microfluidic automation. Microvalves can 
provide fluidic isolation, allowing dynamic reconfiguration, or switching between fluids, flow 
control, and can be configured to work in concert as micropumps. While the literature shows that 
numerous variations of microvalve geometries have been applied to a broad range of applications, 
these previous works generally don’t consider the specific requirements that must be considered 
when working with blood. Hemocompatibility is a critical requirement of any microfluidic system 
designed to operate with blood samples, be this research platforms for investigating the nature of 
blood, facilitating drug discovery for compounds effecting blood function, or sample preparation 
for point-of-care devices.  
Due to the complex protein makeup of blood, interactions with microfluidic devices generally 
result in biofouling, resulting from protein adsorption and cellular interactions with surfaces within 
the microfluidic devices. As a result, blood based microfluidic systems are often considered 
disposable or single use devices, this is particularly relevant in the case of devices investigating 
reactive properties of blood, such as platelet function and thrombus formation. Statistically 
significant biological data requires a high degree of replicate information to allow for statistical 
validation and analysis, as such, blood research requires a high volume replicate microfluidic 
devices. 
This chapter investigates the practicality and design considerations of microfluidic control 
components capable of handling blood without significant deleterious impact at physiologically 
relevant flow rates. This work was the result of a collaborative project with the Australian centre 
for blood diseases, Monash University, and builds on the findings of chapter 3, investigating the 
real-world practicality of handling increasingly complex biological samples. In addition, this work 
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assesses the practicality and scalability of the fabrication technique outlined in chapter 2, 
investigating the practicality of fabricating the large quantities (10’s to 100’s) of single use 
disposable devices required for replicate bioassays.  
 
The research outcomes resulting from this chapter have demonstrated that not only can the 
fabrication technique outlined in chapter 2 facilitate rapid iterative design processes, but in 
addition, provide a level of repeatability and reliability suited to fabrication of large quantities of 
devices that are required to effectively conduct clinical biomedical research. Specifically, early 
prototype device geometries have been rapidly fabricated, and replicates assessed, with a 
turnaround of only a few days enabling numerous design iterations and rapid development. When 
final geometries were identified, a comprehensive battery of assays were conducted, requiring 
hundreds of replicate devices with minimal inter-device variance and within relatively short donor-
defined timeframes.  
These studies allowed additional insight into some caveats associated with the use of normally 
closed elastomer microvalves. These studies identified delamination of microchannel walls at valve 
gate edges as an area of reduced hemocompatibility, presumably due to high transient flow rates 
within these areas, or the mechanical effects these areas had on blood. In order to avoid 
delamination, selective plasma bonding was performed, using an exclusion stamp to selectively 
prevent plasma activation in select areas. While selective plasma bonding allowed fabrication of 
devices not dependant on clamping mechanisms, time dependant adhesion of PDMS to glass 
coverslips [53] did unfortunately limit the shelf-life of lifting gate valves used in blood-based 
studies to approximately two weeks from fabrication. While this issue can be countered by 
reversibly bonding devices closer to the time of their use, this is a challenge that will need to be 
overcome as a requisite for Point of care application. 
As further work beyond the scope of this thesis, I would suggest further exploration of valve 
geometries that optimise opening height with respect to pressure gradient, while also attempting 
to reduce delamination associated with torsion present at the edges of open microvalves. In 
addition, while the use of a material other than PDMS may avoid issues associated with time 
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dependant bonding, investigation of methods avoiding this issue would still be of benefit to 
research platforms constructed using PDMS. 
Current ongoing work, beyond the scope of this doctorate, aims to expand the outcomes of this 
chapter, exploring hemocompatibility of dynamic fluidic actuation components, in the context of 
a blood-based bioreactor for assessment of blood function. While the paper of this Section 
focussed on individual control components for blood handling within microfluidic systems, 
ongoing work is focused toward reconfigurable systems utilising these control components, as well 
as hemocompatible fluid actuation mechanisms. This ongoing work is intended to realise a blood 
function assay, resulting in systems building on the outcomes of this thesis to provide a complex 
multilayer microfluidic system capable of processing and performing blood function assays on 
whole human blood. This work is planned for publication in late 2018 or early 2019, and as such is 
not explored within the scope of this thesis. 
Overall, this chapter highlights that platforms fabricated with the technique outlined in chapter 2, 
are well suited to handling complex biological fluids. This indicates that it is possible to rapidly 
fabricate components suited to sophisticated fluidic manipulation with exceedingly complex 
biological fluids, with the level of reproducibility, and in numbers sufficient to gather statistically 
significant data from a battery of bioassays. This work outlines design considerations for modular 
control components, capable of manipulating blood samples, which could be applied to numerous 
point-of-care, or research applications.  
 
The work related to this chapter has been peer-reviewed and published in: Lab on a chip 
The paper can be obtained via the DOI: 10.1039/C7LC01320E [32] 
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My role in this work was to conceive, design and fabricate microfluidic systems. I was involved in 
experimental design, performed initial mechanical characterisation experiments, assisted with 
initial bio-experiments and assisted with analysis of results, including coordination of several 
different multidisciplinary groups. I assisted with writing the manuscript and contributed several 
figures. This work was heavily multidisciplinary, with mechanical engineering components, seen in 
the computational fluid dynamics, and microparticle image velocimetry. Electronic and 
microsystems engineering components are seen in the device design and fabrication, and creation 
of support equipment such as the valve driver and computer interfaces. Cell biology and clinical 
biomedical components were critical in the comprehensive battery of hemocompatibility assays. 
My leading role in this research was shared with another PhD student, in the field of medicine and 
biology. We worked closely together to facilitate this highly collaborative and multidisciplinary 
work, and this is reflected in us both being listed as co-first authors. 
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This paper reports on the parameters that determine the haemocompatibility of elastomeric microvalves
for blood handling in microfluidic systems. Using a comprehensive investigation of blood function, we de-
scribe a hierarchy of haemocompatibility as a function of microvalve geometry and identify a “normally-
closed” v-gate pneumatic microvalve design that minimally affects blood plasma fibrinogen and von
Willebrand factor composition, minimises effects on erythrocyte structure and function, and limits effects
on platelet activation and aggregation, while facilitating rapid switching control for blood sample delivery.
We propose that the haemodynamic profile of valve gate geometries is a significant determinant of
platelet-dependent biofouling and haemocompatibility. Overall our findings suggest that modification of
microvalve gate geometry and consequently haemodynamic profile can improve haemocompatibility,
while minimising the requirement for chemical or protein modification of microfluidic surfaces. This bio-
logical insight and approach may be harnessed to inform future haemocompatible microfluidic valve and
component design, and is an advance towards lab-on-chip automation for blood based diagnostic
systems.
Introduction
There is an increasing drive toward microfluidic based blood
diagnostics,1–5 however a critical bottleneck impeding clinical
translation of such devices is the ability to reliably deliver
blood components to assay platforms without affecting blood
composition or function.6,7 Microfluidic performance in areas
such as the mechanics of blood cell handling, effects on
blood plasma protein and biomarker composition, materials
haemocompatibility, and haemodynamic parameters, must be
carefully considered in order to achieve effective blood han-
dling. On-chip microvalve operated delivery, mixing, and
pumping elements have the potential to deliver sophisticated,
multiplexed, automated, and reliable haematology focused
microfluidic diagnostics; however the effect of such dynamic
microfluidic components on blood function presents signifi-
cant challenges. While haemocompatibility is a recognized
criterion for microfluidic development, design approaches
have been limited by a lack of sophistication with respect to
the assessment of blood function, and have often relied on
superficial measures such as haemolysis, and gross assess-
ment of biofouling.8,9 Few microfluidic studies have compre-
hensively defined haemocompatibility and virtually none de-
scribe a detailed blood-testing regime to assess and inform
microfluidic device design.10–14
Blood presents significant and specific challenges when
working with microfluidic systems.6,15 Blood is a non-
Newtonian fluid and its viscosity may be up to an order of
magnitude more viscous than water (dependent on flow pa-
rameters and biochemical factors), leading to pressure differ-
entials that may perturb flow and impair device perfor-
mance.16,17 In addition, blood plasma protein physisorption
processes at microfluidic surfaces pose significant problems
with regard to blood analyte (biomarker) loss, and blood cell
adhesion.15 The plasma protein and cellular components of
blood, particularly von Willebrand factor (VWF), fibrinogen,
and blood platelets, have evolved to react to local changes in
the hydrodynamic (haemodynamic) environment through
processes of protein conformational unfolding, surface adhe-
sion and platelet–platelet aggregation.18 VWF binding and
function is critically sensitive to the prevailing
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haemodynamic conditions such that shear rates >5000 s−1
lead to conformational unfolding and presentation of platelet
binding domains.19–21 Fibrinogen exchange at artificial sur-
faces is mediated by competition with proteins of the contact
activation (coagulation) pathway, such as high-molecular-
weight kininogen, factor XII, and plasminogen, with studies
demonstrating that sample flow can significantly increase ini-
tial adsorption rates and also modify exchange rates with co-
agulation factors (the Vroman effect).22–24 Shear rates in rela-
tion to platelet function must be carefully considered.25–27
Elevated shear rates on the order of 1500–10 000 s−1 and ex-
tremes above 50 000 s−1 can directly trigger blood platelet
Ca2+ signalling, α-granule secretion, adhesion, and platelet
aggregation through the activation and engagement of plate-
let adhesion receptors, such as GPIb/V/IX and the integrin
αIIbβ3.
28,29 In addition, platelet adhesion and activation at de-
vice surfaces can trigger coagulation through the generation
of “coated” procoagulant platelets expressing surface phos-
phatidyl serine (PS).30 Significantly, findings from our labora-
tories have demonstrated that shear rate micro-gradients
above a critical threshold can acutely trigger platelet aggrega-
tion in microfluidic systems.31–33
Pneumatically actuated microvalves are the most common
valve type in assays requiring multiplexed integration, as the
fabrication processes are comparatively inexpensive and sim-
ple.34 Pneumatic valves may operate through ‘normally-open’
or ‘normally-closed’ configurations.35 Normally-open configu-
rations may be designed for high-density systems, but are
only possible with low aspect ratio rounded channels; requir-
ing complex fabrication methods.36 In addition, normally
open valves are limited where portability is a requirement
due to the need for bulky ancillary drivers to maintain fluidic
isolation.34 In contrast, normally closed valves are able to
overcome these limitations, and generally operate at lower ac-
tuation pressures (typical actuation pressures of 1–12 psi)
resulting in increased performance and the capability to use
relatively small footprint valve drivers.37 Normally closed
lifting gate valves consist of a vertical gate geometry pat-
terned directly onto a membrane that deflects away from the
channel floor upon actuation.34 This valve configuration al-
lows for reliable fluidic isolation and integration with various
functional substrates,31 with recent advances in fabrication
techniques by our group significantly reducing fabrication
complexity, increasing the practical integration of this valve
type.38 A key consideration for optimised lifting gate valve
performance is actuation pressure, with operating pressure
range in part determined by overall valve geometry.35 A hier-
archy of valve geometries as a function of actuation pressure
and fluidic channel geometry has been defined, such that
v-shaped valves demonstrate the lowest actuation pressures
in comparison to straight or diagonal valve variants.35 In ad-
dition, v-shaped valves are typically more reliable, as they ac-
tuate more consistently, and their actuation pressures are
more reproducible across replicate devices.35 While a number
of design principles focused purely on valve mechanical per-
formance have been identified, the specific requirements for
haemocompatible blood handling microvalves and the im-
pact of valve haemodynamics on performance have not been
investigated.
In this study, we define and describe a biologically in-
formed approach for haemocompatible microfluidic design.
Using this approach, we identify a v-shaped microvalve archi-
tecture that minimally impacts blood sample integrity and
function without the requirement for surface passivation
(prefouling).
Experimental
Device description
The overall design of the microvalve iterations tested, the
“test-manifolds”, and the pneumatic actuation chamber loca-
tion are shown in Fig. 1a. Valve iterations were identified by
the width of the valve chamber (μm) and overall geometry as;
S300, S400, S500 and S600 (straight valves) and V300, V400,
V500 and V600 (v-shaped valves) (Fig. 1a). Details of valve
manifold dimensions are given in Table S1.† Under normal
operation sample perfusion through the valve test-manifold
was driven via an external Harvard PHD-2000 syringe driver,
operating in withdraw mode, connected to the outlet channel
in the PDMS block using a 30 ml glass syringe attached to 10
cm of Tygon (0.8 mm I.D.) tubing. In the case of FACS based
assays or assays requiring perfusate collection, blood samples
were loaded into sterile plastic 10 mL syringes prior to device
connection and the syringe driver operated in infuse mode.
Pneumatic gate operation was achieved by applying negative
pressure through connection of a 50 ml plastic syringe to the
actuation chambers by 10 cm of Tygon tubing.
Device fabrication
Fabrication of microfluidic devices was achieved using a pre-
viously described method.38 In brief, a combination of a
membrane-sandwich fabrication method and PDMS injection
moulding, was utilised to produce thin double sided PDMS
slabs.38 Standard photolithography techniques33 were used to
fabricate the required complementary mould structures,
using silicon and glass wafer substrates. These moulds
consisted of primary fluidic channels and valve gates pat-
terned onto the bottom mould, and pneumatic actuation
channels and viaducts on the transparent upper mould. Poly-
dimethylsiloxane (PDMS) pre-polymer (Sylgard 184 Silicone
Elastomer – Dow Corning) was mixed with curing agent with
a weight ratio of 10 : 1, and thoroughly degassed under vac-
uum. Degassed pre-polymer was introduced between the
moulds, which were aligned, clamped and cured for 30 min
at 100 °C. Following curing, the moulds were separated and
the PDMS slab extracted. Interface holes were biopsy
punched as required, and a 5 mm thick interface slab of
PDMS was plasma bonded to the upper surface of the injec-
tion moulded PDMS slab (Harrick Plasma PDC-002: 100% O2,
1 min). The interface slab, previously biopsy punched with
corresponding 750 μm interface holes, acted to seal the pneu-
matic upper channels while providing the fluidic and
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pneumatic interface. A no. 1 borosilicate coverslip sealed the
bottom of the injection-moulded slab and acted as the imag-
ing window for microscopy-based experiments. Selective
plasma bonding was achieved in a manner similar to those
previously described for normally closed PDMS microvalves.
In order to selectively prevent permanent plasma bonding of
the valve gates, PDMS exclusion stamps were fabricated using
photolithography to define a block with raised 150 μm tall
pillars with geometry to match the location and size of all
valve gates on the bottom of the injection moulded PDMS
slab.39 This exclusion stamp is aligned and placed over the
valve gates prior to plasma treatment (100% O2, 20 seconds)
and allows plasma access to all PDMS surfaces with exception
of the areas in contact with the exclusion stamp.
Computational fluid dynamic analysis
To conduct CFD analysis at the actuated microvalve assem-
bly, the valve and microfluidic geometry were simplified and
reconstructed from 3-dimensional confocal imaging data of
valve assemblies perfused with TRITC (1 μg mL−1) in mQ
H2O. Confocal images were exported as StereoLithograpy (stl)
files using the open source software Fiji. The stl file was fur-
ther optimized using surface reconstruction algorithms in
MeshLab. Simplified reconstructions of the open valve geom-
etry were then constructed based on these optimized stl files,
using the CAD software, Solidworks (Dassault Systèmes). The
mesh was constructed using snappyhexmesh resulting in a
total of 16 136 cells (12 340 hexahedra and 3796 polyhedra).
Grid convergence analysis was performed at the valve gate
wall, using centerline flow profiles (Fig. S2†). To determine
the local shear rate conditions for human whole blood at the
micro-valve structure the Navier Stokes equations over the ge-
ometry domain were solved using OpenFOAM and SIMPLE al-
gorithm, using a viscosity of 0.00345 Pa s and a density of
1050 kg m−3. Blood can be approximated as Newtonian fluid
at high shear rates.39 Non-slip at the wall was considered.
Fig. 1 Test device description and microvalve mechanical testing. a. DIC micro-image showing the straight and v-gate test-manifolds. The
microfluidic test-manifolds consisted of five primary fluidic channels; a control (no-valve) channel, and four channels containing lifting-gate valves
differing by the width of the valve chamber and channel expansion, including 300 μm, 400 μm, 500 μm and 600 μm. b. Confocal imaging of S300
and V300 microvalves in partially open state following perfusion with TRITC (1 μg mL−1). Views show 3-dimensional reconstructions of S300 and
V300 valve cases. Note the overall deformation of the valve gates under negative pressure resulting in microchannel clearance. c. Confocal imaging
showing top down and lateral (midline) views of S300 and V300 gates in fully open and closed states. Note that opening heights were taken from the
lateral midline. d. Valve opening height (midline) as a function of actuation pressure for v-gate valve manifolds. Numbers in brackets represent gate
projection into the microchannel at a maximal actuation pressure of 7.37 psi. e. Valve opening height (midline) as a function of actuation pressure for
straight valve manifolds. Numbers in brackets represent gate projection into the microchannel at a maximal actuation pressure of 7.37 psi.
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μPIV analysis
μPIV analysis was performed in order to verify and support
CFD models. Detailed methodology is supplied in ESI.†
High speed platelet imaging
Washed platelets (200 × 109/L) were loaded with DiOC6 (2 μg
ml−1) for 10 min at 37 °C. Dye-loaded platelets (final platelet
count = 200 × 109/L) were then reconstituted with isolated RBC
prior to perfusion through the device. Platelet adhesion and acti-
vation were blocked with theophylline (10 mM) and eptifibatide
(Integrilin-20 μg mL−1). Reconstituted blood samples were per-
fused across the valve surface at a rate of 24 μl min−1 for 16 s.
Epifluorescence (488ex/510em) images were acquired at 1100 fps
(1280 × 1024) using a Phantom v1610 (Vision Research) CMOS
camera attached to an Olympus IX83 microscope (UPLSAPO
60×/NA1.260 obj) with Spectra 4 light source. Images were com-
piled as maximum z-projections off-line in ImageJ.
Blood collection and handling
Ethics approval was obtained from the Alfred Hospital and
Monash University Standing Committees on Ethics in Research
involving Humans. All experiments were performed in compli-
ance with relevant laws and guidelines and followed Monash
Universities policies regarding the handling of human blood
samples. Whole blood samples were obtained from consenting
subjects via venesection into 2% w/v citrate. Samples were
allowed to rest for 10 min at 37 °C prior to device perfusion.
Full blood examination was routinely conducted using a
Haemogram (Abbott Diagnostics) blood analyser prior to exper-
imentation and blood haematocrit and platelet count recorded.
Assessment of valve dependent platelet aggregation
To assess platelet aggregation as a function of valve architecture
human whole blood samples were incubated with the lipophilic
membrane dye DiOC6 (1 μg mL
−1) (Molecular Probes) and 0.02
U mL−1 apyrase (to eliminate released ADP during blood collec-
tion) for 10 min at 37 °C and subsequently perfused through
the device at constant flow rates of 24 or 108 μL min−1. Blood
perfusion and platelet aggregation dynamics were acquired on
an inverted Nikon TiU microscope (Nikon Plan Fluor 20×/0.50
objective) using an Andor Zyla sCMOS camera at 1 fps for 210
s. All image analysis was performed off-line in ImageJ using
Huang's fuzzy image thresholding. DiOC6 labelled fluorescent
platelet aggregates were auto-thresholded such that the earliest
micro-aggregates were included in the analysis window. Platelet
aggregate size was expressed as either 2-dimensional cross sec-
tion (μm2) or integrated intensity as a function of time (s).
Platelet isolation
Washed human platelets were isolated from human whole
blood as described.40 Whole blood was collected into acid cit-
rate dextrose (ACD) anticoagulant at a ratio of 6 : 1 (blood/
ACD), to which 20 U ml−1 enoxaparin (Clexane) was added be-
fore being allowed to incubate at 37 °C for 15 min. Separation
of platelet-rich plasma (PRP) and red blood cells (RBC) was
achieved by centrifugation at 300 × g for 16 min. Platelets were
isolated from PRP by centrifugation at 1700 × g for 7 min,
followed by resuspension in an equal volume of platelet wash-
ing buffer (4.3 mM K2HPO4, 4.3 mM Na2HPO4, 24.3 mM
NaH2PO4, 113 mM NaCl, 5.5 mMD-glucose, and 10 mM the-
ophylline, pH 6.5). Platelets were washed by centrifugation at
1500 × g for 7 min, followed by a final resuspension at a con-
centration of 200 × 109/ml in Tyrode's buffer (10 mM Hepes, 12
mM NaHCO3, 137 mM NaCl, 2.7 mM KCl, and 5 mM glucose,
pH 7.3) containing bovine serum albumin (5 mg ml−1), calcium
(1 mM), and apyrase (0.02 units per ml) (ADPase activity).
Reconstituted blood sample preparation
Reconstituted blood was prepared from human whole blood as
described.40,41 RBC were isolated by centrifugation at 200 × g
for 15 minutes, and the PRP fraction collected. The remaining
RBC fraction was washed 2× with Tyrode's buffer pH 7.2 via
centrifugation at 1700 × g for 7 minutes. The final RBC fraction
was re-suspended in Tyrodes pH 7.2 supplemented with 0.5%
w/v BSA + apyrase (0.02 U mL−1) and carried through a final
centrifugation at 1700 × g for 7 minutes. Packed RBC were
stored at 37 °C for later use. Reconstituted blood samples were
prepared using either isolated platelet suspensions in Tyrodes
buffer pH 7.2 or autologous PRP at a final haematocrit (Hct) of
40% and a platelet count of 200 × 109/L. Hct and platelet
counts were verified by full blood analysis.
Platelet and erythrocyte Ca2+ assay
Platelet cytosolic calcium levels [Ca2+]c were monitored
according to published methods.40 Briefly, washed platelets
(1 × 109/mL) were loaded with Oregon Green BAPTA 488
1,2-bis (2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid
tetraĲacetoxymethyl) ester (1 μM), and Fura-Red/AM (1.25 μM)
for 30 min at 37 °C. Dye-loaded platelets (final platelet count
= 200 × 109/L) were then reconstituted with washed red blood
cells prior to perfusion through the device. Reconstituted
blood samples were perfused through the test-manifold at Q
= 24 or 108 μL min−1.
RBC used for monitoring intracellular calcium changes in
response to shear stress were washed with modified Tyrodes
pH 7.2 + 2 mM CaCl2 and 10 mmol l
−1 glucose then re-
suspended in this buffer at a haematocrit of 0.002%. Fluo-4/
AM dissolved at 2 mM in dimethyl sulfoxide was added to the
RBC suspensions to obtain 3 μM and the suspensions were in-
cubated with mild shaking for 1 hour at 37 °C. RBC were
washed three times with supplemented Tyrodes following the
incubation period and then suspended in supplemented
Tyrodes. To examine changes in calcium flux, sequential confo-
cal images of platelets or RBC were captured at a scan rate of
0.586 frames per s for 37.5 s over the 3.5 min perfusion time
course at positions upstream, at the valve, immediately down-
stream and 1000 μm downstream of the valve structure. Stan-
dard image thresholding was used to demarcate RBC or plate-
lets from the background and determine calcium dye
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fluorescence. In the case of RBC Fluo4 fluorescence was moni-
tored and fluorescence change normalised against resting (no
perfusion) controls. In the case of platelets, the fluorescent ra-
tio of Oregon Green BAPTA 488 to Fura Red was then calcu-
lated. Real time platelet calcium flux was calculated from
ratiometric fluorescence measurements and converted to intra-
cellular calcium concentrations (nM) as described previously.42
Haemolysis assay
Whole blood samples in 3.2% ACD collected following perfu-
sion through the valve test platform were centrifuged at 500 ×
g for 5 minutes, and the resulting supernatant collected. The
supernatant was subsequently centrifuged at 500 × g for 5 mi-
nutes, to pellet any intact RBC. 15 μL of each supernatant
was then suspended in 185 μl 1% Tyrodes (4.3 mM K2HPO4,
4.3 mM Na2HPO4, 24.3 mM NaH2PO4, 113 mM NaCl, 5.5 mM
D-glucose, pH 7.2) at 35 °C. A positive control was made by
adding 15 μL of non-haemolysed haematocrit and 10 μl Tri-
ton X-100 to 185 μl of Tyrodes buffer. A negative control
consisted of the collected supernatant of an unprocessed
sample. 100 μl of each sample was then transferred to a clear,
flat-bottomed 96-well plate and absorbance (495 nm) was
measured. Background correction was determined from the
average absorbance of the negative control samples. All sam-
ples were normalised with the positive control representing
100% haemolysis.
Plasma protein assay
To assess plasma VWF loss as a function of valve performance
whole blood samples (500 μL) in 3.2% ACD were collected fol-
lowing perfusion through the valve test platformĲs). Blood
samples were centrifuged at 2000 × g for 2 min and the
plasma fraction retained. Plasma VWF antigen (%) was deter-
mined via von Willebrand factor ELISA (Helena laboratories)
as per the manufacturers instructions. To determine the effect
of valve architecture on VWF multimer profile samples were
collected as per ELISA and subsequently run on an agarose
multimer gel and multimer range assessed via densitometry.
Erythrocyte and platelet FACS analysis
Whole blood samples in 3.2% ACD following perfusion
through the valve test platform were collected. 5 μl samples
from each valve iteration were immediately transferred to 12
× 75 mm Falcon® capped polystyrene test tubes containing
20 μL CD61 PerCP, 20 μL PAC-1 FITC or 5 μL PE-P selectin
conjugated monoclonal antibodies. Tubes containing only
one of each antibody were prepared using inactivated blood
to act as voltages, tubes containing blood activated with 2 ×
10−5 M ADP were used for channel compensation, and tubes
stained only with CD-61 were used to obtain isotype control
forward and side scatter buffers. For all samples containing
PAC-1 antibodies, RGDS was also added to the solution to ex-
clude non-specific binding. Data was then analysed in two-
colour plots.
Statistical analysis
Statistical analysis was performed in GraphPad Prism using a
one-way analysis of variance (ANOVA) with Dunnett's multi-
ple comparisons test to compare means and determine
significance.
Multiple regression analysis was performed using SPSS sta-
tistics. All variables were coded as continuous except the valve
type, which was coded as an ordinal variable. Continuous re-
sults were assumed to have a normal distribution (using a
normal probability plot), linearity (using a residual plot) and
constant variability (using a scatter plot). All variables were
entered into the analysis. The R2 for this multivariate analysis
was 0.780, showing the regression explained 78.0% of the var-
iance in the data. F-Test demonstrated a high degree of signif-
icance (F = 116.218), allowing the assumption that the model
explained a significant degree of variation in the data. All
groups demonstrated statistical significance (p < 0.05). Non-
multicollinearity was confirmed. Standardised coefficients
were compared to determine the impact of variables.
Results
Valve gate mechanical performance
To characterise micro-valve performance as a function of ac-
tuation pressure we conducted scanning confocal microscopy
experiments in which valve manifolds were perfused with a
tetramethylrhodamine (TRITC) solution (1 μg mL−1) and valve
opening recorded in 3-dimensions (Fig. 1b and c; Video S1†).
Fig. 1b and c demonstrate that application of negative pres-
sure in the actuation chamber results in the upward deforma-
tion and expansion of the actuation membrane, lifting and
asymmetrically stretching the valve gates resulting in an
“arched” opening profile. Valve opening efficiency (measured
at mid-line) as a function of actuation pressure directly corre-
lated with valve geometry such that S600 and V600 valves
demonstrated the greatest opening efficiency, with full gate
clearance (100 μm) occurring at an actuation pressure of
⋍4.9 psi (Fig. 1d and e). Significantly, overall valve chamber
width appeared to be a direct effector of opening efficiency,
with valves in the range of 300–500 μm only partially opening
at an applied pressure of ∼4.9 psi (Fig. 1d and e). It should
be noted by the standard deviation that valve-to-valve vari-
ance was evident due both to batch-to-batch differences in
fabrication and also the inherent tolerances of PDMS based
elastomeric micro-valves. Head-to-head comparison of
straight versus v-shaped valves demonstrated that the
v-shaped design more reliably actuated at low pressures, with
the v-shaped design displaying a lower overall minimum ac-
tuation pressure (Fig. 1d and e). Furthermore, as evidenced
by the variance in replicate measurements the v-gate geome-
try typically actuated more consistently across the applied
pressure range (Fig. 1d and e). Confocal imaging demon-
strated that at an opening pressure of −7.37 psi the 300–500
μm wide valve gates projected up to ∼5–55 μm into the
microfluidic channel, increasing the likelihood of valve gate
interactions with perfused blood components (Fig. 1d and e).
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Effect of valve architecture on platelet aggregation and fouling
A key problem associated with microfluidic blood handling
performance is fouling due to adhesion and/or aggregation
of blood cells, particularly platelets, with component systems.
To investigate the effects of valve architecture on platelet ad-
hesion and aggregation we perfused both straight and
v-shaped test-manifolds with citrated whole blood for up to 5
minutes. Fig. 2a and b demonstrate that for fully open and
partially open states, platelet aggregation inversely correlates
with valve gate size, such that 300 μm valves show the
highest levels of platelet adhesion/aggregation. Head-to-head
comparison of straight versus v-shaped valves demonstrated
that straight valves are significantly more pro-aggregatory
than v-shaped in fully open and partially open (40 μm) states
(Fig. 2a and b). The V600 geometry demonstrated limited
platelet adhesion/aggregation above that observed for no-
valve controls in the fully open state (Fig. 2a). Epi-
fluorescence imaging of the early platelet adhesion response
demonstrated that platelet aggregation was initiated at the
upstream edge and bottom face of valve gates (Video S2†).
Furthermore, early aggregates formed as distinct “platelet
strings” that in the case of straight gates were distributed
across the entire bottom face (Video S3†). In the case of v-
gates, “platelet strings” formed lateral to the v-gate apex,
which was free of formed aggregates (Video S2†).
3-Dimensional confocal imaging of platelet recruitment at the
valve gate geometries following prolonged (5 min) blood per-
fusion demonstrated that platelet fouling was localised pri-
marily at the bottom face of the valve gates with consolidated
aggregates extending freely away from both the upstream and
downstream faces (Fig. 2d–g). Quantitation of the time to
complete fouling in the fully open and 40 μm states demon-
strated that straight valve designs were more prone to occlu-
sion as a function of valve size compared to v-gates (Fig. 2c).
A 5-fold increase in flow rate (Q = 128 μL min−1) led to an ap-
proximate doubling in overall platelet aggregation at the
v-gates across the size range tested (Fig. 3a and S3a†). In-
creasing haematocrit (Hct) from 40–60% led to an overall in-
crease in platelet aggregation dependent on geometry and in-
versely with valve size (Fig. 3b and S3b†). Increasing platelet
count led to an overall increase in platelet aggregation that
scaled inversely with valve size (Fig. 3c and S3c†). Taken to-
gether these data suggest that, as for laminar flow systems,
platelet margination (increased density at the wall) and mass
transport effects due to red blood cell interactions may con-
tribute to the aggregation response. There was no effect of
anticoagulant (citrate versus hirudin) on the observed platelet
response (Fig. S4†). Multivariate regression to predict aggre-
gate size from; valve geometry (categorical), and open state,
valve size, Hct, platelet count, and flow rate (continuous)
demonstrated that all variables statistically significantly
Fig. 2 Platelet aggregation and biofouling as a function of microvalve geometry. a. Platelet aggregation at straight versus v-gates in fully open states;
Q = 24 μl min−1. b. Platelet aggregation at straight versus v-gates in partially open (40 μm) states; atQ = 24 μl min−1. Black horizontal bars indicate com-
parative valve shapes and sizes (e.g. V300 and S300) for which a significance significant difference was tested for using a paired t-test. * p≤ 0.05, ** p
≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001. c. Occlusion times of straight versus v-gates in fully open or partially open (40 μm) states; Q = 24 μl min−1. d–g.
3-Dimensional reconstructions of confocal microscopy epifluorescence images of representative aggregate formation, imaged after 5 minutes of blood
flow. Aggregates are represented in green and the valve geometries in red. Scale bar represents 100 μm. d. V300 partially open valve with aggregate. e.
S300 partially open valve with aggregate. f. V600 partially open valve with aggregate. g. S600 partially open valve with aggregate.
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affected aggregate size [F(7,236) = 79.593, p < 0.05, R2 =
0.780] (Table S2†). This analysis demonstrated that valve cate-
gory was a significant effector of haemocompatibility (Table
S2†) (β = 1.041 for straight valves, 0.750 for v-shaped valves).
Taken together this data suggests that near wall platelet ad-
hesion and aggregation and hence fouling can be signifi-
cantly modulated by changes in valve geometry.
Effect of valve architecture on platelet activation
An important consideration for microvalve performance is
the effect that valve haemodynamics have on platelet activa-
tion in bulk flow, particularly where downstream cell and bio-
marker assay are required. To investigate the impact of
micro-valve design on platelet activation we examined the im-
pact of valve architecture on platelet Ca2+ signal transduction
in bulk flow (Fig. 4a and S5a†). Maximal platelet [Ca2+]c (a
global marker of platelet activation status) inversely correlated
with valve size, with the straight valve architecture more reac-
tive than v-shaped, in both fully open and partially open (40
μm) states (Fig. 4a and S5a†). Fig. 4b–d (Fig. S5b–d†) demon-
strate that as per platelet [Ca2+]c distinct markers of platelet
function; platelet integrin αIIbβ3 activation (PAC1 binding),
α-granule secretion (P-selectin expression), and platelet
procoagulant function (phosphatidyl serine exposure) mapped
to valve size and shape, suggesting that global platelet function
in the bulk flow is significantly affected by valve geometry.
Effect of valve architecture on blood plasma VWF and
fibrinogen
Platelet adhesion and aggregation is critically driven by the
shear dependent binding and unfolding of plasma VWF and
Fig. 3 Platelet aggregation in bulk flow as a function of microvalve geometry. a. Platelet aggregation at straight versus v-fully open gates at Q = 24
μl min−1 and 128 μl min−1. b. Platelet aggregation at straight versus v-fully open gates (Q = 24 μl min−1) as a function of hematocrit. c. Platelet aggre-
gation at straight versus v-fully open gates (Q = 24 μl min−1) as a function of platelet count. All data shows n= 3 independent experiments normal-
ized to valve surface area (μm2). Error bars indicate standard deviation. Black horizontal bars indicate comparative valve shapes and sizes (e.g. V300
and S300) for which a significance significant difference was tested for using a paired t-test. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001.
Fig. 4 Platelet activation in bulk flow as a function of microvalve geometry. a. Maximal platelet cytosolic calcium flux [Ca2+]c (nm) under perfusion
at Q = 24 μl min−1 in the fully open and partially open (40 μm) states (n= 3 independent experiments). b. Fluorescence activated cell sorting (FACS)
analysis showing mean fluorescence intensity (MFI) geomean distribution of FIT-C PAC-1 antibody binding (integrin αiibβ3 activation) to platelets in
human whole blood following perfusion through V300, S300, V600 and S600 gates (Q = 24 μl min−1) in the fully open and partially open (40 μm)
states. c. FACS analysis showing MFI geomean distribution of FITC-annexin-v binding to platelets in human whole blood following perfusion
through V300, S300, V600 and S600 gates (Q = 24 μl min−1) in the fully open and partially open (40 μm) states. d. FACS analysis showing MFI
geomean distribution of expression of P-selectin antibody binding to platelets in human whole blood following perfusion through V300, S300,
V600 and S600 gates (Q = 24 μl min−1) in the fully open and partially open (40 μm) states. All data indicates n= 3 independent experiments normal-
ized to valve surface area. Error bars indicate standard deviation. Black horizontal bars indicate comparative valve shapes and sizes (e.g. V300 and
S300) for which a significance significant difference was tested for using a paired t-test. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001.
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the surface immobilisation of fibrinogen.42 To investigate the
effect of valve design on plasma VWF and fibrinogen, valve test
manifolds were perfused with whole blood or platelet poor
plasma (PPP) and VWF or fibrinogen concentration in the flow-
through assessed pre- and post-perfusion. Fig. 5a demonstrates
that perfusate VWF antigen loss directly correlated with valve
gate size, such that the 300 μm valves show the highest levels
of loss. Head-to-head comparison of straight versus v-shaped
valves demonstrated that straight valve designs led to signifi-
cantly more VWF loss than v-shaped (Fig. 5a). VWF multimer
analysis demonstrated no preferential loss of higher molecular
weight multimers (data not shown). PPP experiments demon-
strated that VWF loss was not dependent on the presence or
absence of platelets or erythrocytes (Fig. 5a). Fig. 5b demon-
strates that while perfusate fibrinogen loss did not correlate
with valve gate size, loss was significantly greater (∼2-fold) for
straight valve geometries in comparison to v-gate. Treatment of
the valve test manifolds with BSA to block the PDMS surface
completely blocked both VWF antigen and fibrinogen loss
demonstrating that both are driven by competitive surface
physisorption mechanisms (Fig. 5a and b).
Effect of valve architecture on erythrocyte handling
Erythrocyte (red blood cell – RBC) stability in the context of
microfluidic systems is critical, particularly where platelet as-
says are concerned, due to the propensity of RBC's to secrete
potent platelet activators such as ADP and ATP upon mechan-
ical activation and haemolysis. Subtle changes in RBC [Ca2+]c
and PS exposure have been demonstrated to correlate with
increasing RBC mechanical fragility and overall reduction in
RBC deformability.43 To investigate the overall mechanical
stability of RBCs as a function of valve design, isolated RBC
at a Hct = 40% were perfused through the test manifolds and
haemolysis assessed for an actuation duty cycle of 1 Hz over
200 s. Fig. 6a demonstrates that the straight valve design
shows poorer RBC mechanical handling, while v-shaped de-
signs demonstrated no increase in haemolysis over no-valve
controls. Increasing the overall size of the straight valve case
completely eliminated valve-dependent haemolysis (Fig. 6a).
RBC echinocyte formation was inversely correlated with valve
size, with v-shaped valves displaying less echinocyte forma-
tion in comparison to straight valves (Fig. 6b). Fig. 6c demon-
strates a marginal but significant increase in RBC [Ca2+]c that
was gate-size dependent, with the S300 valve in the 40 μm
open state showing a significant increase in RBC [Ca2+]c in
comparison to the V300 case. Measurement of correlated
RBC PS exposure demonstrated RBC procoagulant function is
dependent on valve geometry and size, with the S300 gate at
40 μm opening showing a significant increase in RBC PS ex-
pression (Fig. 6d). Taken together this data demonstrates
that RBC mechanical stability and activation status is sensi-
tive to valve gate architecture and overall valve size; signifi-
cantly v-shaped valves were superior across the tested size
range.
Valve geometry effects predicted blood shear rate exposure
Previously published studies from our laboratories and
others demonstrate that shear rate (both peak shear rate and
potentially shear rate gradients) significantly affect blood
platelet function and VWF structure, particularly at micro-
fluidic step geometries.31–33 Based on our blood assay find-
ings we therefore hypothesised that shear rate magnitude
(both at the wall and bulk flow) and/or shear rate gradients
may play a role in determining the observed effects on blood
function. To examine this hypothesis while isolating the vari-
ables of microvalve geometry from opening height we
conducted a series of computational fluid dynamic (CFD)
simulations in which gate-opening height was fixed at 40 μm.
Valve mesh generation for CFD was derived from simplified
3-dimensional reconstructions of confocal imaging data (see
Fig. 5 Plasma protein physisorption and composition as a function of microvalve geometry. a. VWF antigen activity loss (μ ml−1) in whole blood
and PPP samples following perfusion through valve manifolds at 24 μl min−1, compared to no-valve control. b. Plasma fibrinogen loss (mg/100 ml)
in whole blood and PPP samples following perfusion through the valve manifolds at 24 μl min−1, compared to no-valve controls. All data indicates
n= 3 independent experiments normalized to valve surface area. Error bars indicate standard deviation. Black horizontal bars indicate comparative
valve shapes and sizes (e.g. V300 and S300) for which a significance significant difference was tested for using a paired t-test. * p≤ 0.05, ** p≤
0.01, *** p≤ 0.001, **** p≤ 0.0001.
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Methods) and was in part validated using μPIV (Fig. S1a–d†).
CFD demonstrated that shear rate contours both at the
microvalve gate walls but also within the cross-section of the
gate are distinct for straight versus v-shaped valves
(Fig. 7a and b and S6a and b†). High wall shear rates (wsr)
were found to be distributed relatively uniformly (in the flow
direction) across the S300 gate surface (wsr maxima >8750
s−1) [Fig. 7a]. In contrast, v-shaped valves displayed a narrow
band of high wsr (>10 000 s−1) only at the upstream edge of
the valve gate that rapidly reduced across the gate surface
(Fig. 7b). In both cases wsr was reduced where the microvalve
gates met the side walls (Fig. 7a and b). Examination of the
shear rate contours in cross-section of the gate predicted a
relatively larger region of reduced shear rate for the v-gate
cases in comparison to straight (Fig. 7a and b insets),
suggesting that blood components passing through this re-
gion of bulk flow will experience overall lower shear rate ex-
posure at the v-gates in comparison to the straight valve ge-
ometry. CFD analysis of 600 μm valve cases showed a similar
trend to that of the 300 μm cases but with a reduction in
overall wsr and bulk flow shear rate magnitude (Fig. S6a and
b†).
Valve geometry effects predicted platelet (particle) trajectories
To model the potential impact of gate geometry on individual
platelet trajectories and shear rate exposure, we simulated
the trajectories of 15 particles of 2 μm diameter (representa-
tive of 2 μm discoid platelets). These particles were released
along discrete horizontal planes at incremental distances
from the upstream microchannel wall, with particle 1 at the
centreline and particle 15 at the lateral margin (Fig. 7c and d
and S6c and d†). Analysis of particle trajectories across the
gate geometries with particles released at planes of 40 μm
and 3 μm from the gate ceiling suggested a rough equiva-
lence of peak shear rate as a function of height for both
straight and v-gate cases (Fig. 7c and d and S6c and d†).
However, while trajectories were uniformly distributed across
the straight gate at 40 and 3 μm release heights; with some
trajectory convergence due to the arched open valve geome-
try, v-gate cases demonstrated marked divergence of trajecto-
ries across the gates at 40 μm and significant convergence at
3 μm (Fig. 7c and d and S6c and d†). This effect was pre-
dicted to initiate across the vertical upstream aspect of the
v-gates (Fig. 7c and d and S6c and d†). High-speed epi-
fluorescence imaging (see Methods) of platelet trajectories in
whole blood (Q = 24 μL min−1) at mid-plane (approximately
40 μm) from straight and v-shaped valves supported our CFD
modelling results and demonstrated that in the presence of
normal Hct, plasma, and cellular components discoid free-
flowing platelets display marked divergence across the v-gate
surface, in contrast platelet trajectories diverged downstream
of the straight gate margin (Fig. 7e and f and S6e and f; Video
S4†).
Our CFD modelling results, in conjunction with our plate-
let adhesion/aggregation experiments, led us to hypothesise
that the v-gate geometry may alter platelet trajectories and
shear rate exposure over time, increasing haemocompatibility
by limiting both the duration of exposure to elevated shear
rate and contact with the gate surface. To explore this hy-
pothesis further we extrapolated platelet (particle) shear rates
v time and platelet distribution as a function of z (distance
Fig. 6 Erythrocyte mechanical stability and activation as a function of microvalve geometry. a. Erythrocyte (RBC) hemolysis (% of lysed +ve
control) for straight and v-shaped valve cases at an opening duty cycle of 1 Hz (Q = 24 μl min−1). b. RBC echinocyte formation (total number of
echinocytes per field) in blood films taken following isolated RBC (40% Hct) perfusion for V300, S300, V600 and S600 cases in the fully open state
(Q = 24 μl min−1). c. Maximal RBC cytosolic [Ca2+]c (arbitrary fluorescence units – AFU) as a function of human whole blood perfusion through
valve gates (Q = 24 μl min−1) in full open and partially open (40 μm) states. d. FACS analysis showing MFI geomean distribution of FITC-annexin-v
binding to isolated RBC (40% Hct) following perfusion through straight and v-gates (Q = 24 μl min−1) in the fully open and partially open (40 μm)
states. All data indicates n= 3 independent experiments normalized to valve surface area. Error bars indicate standard deviation. Black horizontal
bars indicate comparative valve shapes (e.g. V300 and S300) for which a significance significant difference was tested for using a paired t-test.
Longer error bars at the top of the figure indicate comparative valve sizes (e.g. V300 and V600) for which a significance significant difference was
tested for using a paired t-test. * p≤ 0.05, ** p≤ 0.01, *** p≤ 0.001, **** p≤ 0.0001.
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from the gate surface) for particles released 3 μm from the
upstream microfluidic ceiling. Our modelling demonstrated
that for two sample particles released (particle 1 at
centreline–particle 15 at the lateral margin) the shear rate v
time profiles in the straight gate case is relatively symmetric
in the flow direction with shear rate peaks at the upstream
and downstream edges of the gate surface (Fig. 8a and c and
S7a and c†). In contrast, the v-gate cases demonstrated asym-
metric shear rate v time profiles with rapid peaks at the up-
stream gate edge followed by a steady reduction in shear rate
across the gate surface (Fig. 8b and d and S7b and d†). This
difference was reflected in the shear gradient data (shear rate
v time plots) (Fig. 8a–d and S7a–d†). Mapping of platelet ag-
gregate distribution as a function of predicted gate wsr, for
straight and v-gate cases, demonstrated a direct correspon-
dence of overall platelet recruitment with shear rate distribu-
tion, with peak recruitment occurring towards the centreline
for straight gate cases while translated laterally for v-gates
(Fig. 8e and f and S7e and f).
To investigate the effect of gate geometry on particle tra-
jectories in the z-plane (relative to the gate surface) we extrap-
olated particle trajectories from CFD analysis for equidis-
tantly spaced particles released in a horizontal plane 3um
from the upstream channel ceiling. Fig. 8g and h demon-
strate that for the v-gate cases, particles released 3 μm from
the upstream ceiling are displaced between 3–8 μm from the
v-gate surface while converging toward the v-gate apex in the
x, y, while in the straight gate case particles were predicted to
remain 3 μm from the gate surface, with minimal conver-
gence. This indicates that the v-gate geometry may effect
Fig. 7 Computational fluid dynamic (CFD) analyses of 300 μm straight versus v-gate geometries. a. 3-Dimensional shear contour profiles of S300
gate geometry at Q = 24 μl min−1 and opening height of 40 μm. Note the peaks in shear rate at the upstream and downstream edges of the
straight gate and the overall elevation in shear rate across the straight gate surface. b. 3-Dimensional shear contour profiles of V300 gate geome-
try at Q = 24 μl min−1 and opening height of 40 μm. Note the initial peak in shear rate at the midline upstream face of the gate surface and overall
reduced shear rates. Note the generation of a low shear rate pocket that extends across the microchannel cross-section. c. Particle shear rate for
fifteen 2 μm particles released 40 μm and 3 μm from the microchannel ceiling for the straight gate case. Note the parallel particle trajectories
across the gate surface. d. Particle shear rate for fifteen 2 μm particles released 40 μm and 3 μm from the microchannel ceiling for the v-gate case.
Note the “funneling” for particles released at 3 μm towards the valve gate midline. Note the loss of funneling at 40 μm from the microchannel ceil-
ing and divergent particle trajectories across the v-gate surface. e. Superimposed image of particle trajectories taken from 16 seconds of flow in
partially open S300 valves. f. Superimposed image of particle trajectories taken from 16 seconds of flow in partially open V300 valves.
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Fig. 8 Shear analyses of 300 μm straight versus v-gate geometries. a–d. Particle shear rate (s−1) v time (black line) and shear rate gradient (s−1/s)
(blue line) plots for particles released 3 μm from the microchannel ceiling. Particle 1, released at the channel midlines is shown in the straight ge-
ometry (a) and v-gate (b), while particle 15, released at the lateral margin, close to the channel sidewall, is shown for the straight geometry in (c)
and the v-gate in (d). Note the symmetric shear rate and shear rate gradient profiles for the straight case versus the asymmetric distribution and
the overall reduction in peak shear rate for the v-gate. Particle 15 in both cases displayed extended shear profiles due to sidewall effects and the
overall upward deformation of the valves in the open state. e and f. Plots of maximal platelet aggregation (black line) and wall shear rate (grey line)
across the S300 partially open (40 μm) (e) and V300 partially open (f) as a function of distance from the valve midpoint. All data shows n= 3 inde-
pendent experiments. Error bars indicate standard deviation. g and h. Cross sectional particle distribution for particles released 3 μm from the
microchannel ceiling, plotting valve open height at a vertical cross-section along the centre of the valve gate (blue) and particle location at this
given plane (red dots) for the v-gate (g) and straight valve geometry (h). Note the lateral convergence and vertical displacement away from the
gate surface present in the v-gate case, while the straight geometry experiences only minor convergence and particles remain within 3 μm.
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overall platelet distribution relative to the gate surface, and
therefore the likelihood of platelet-gate surface interactions.
Comparison of platelet aggregate distribution as a function
of predicted z-position from the gate surfaces (Fig. 8e–h), for
straight and v-gate cases, demonstrated an inverse correlation
of overall aggregate position with z-displacement, with mini-
mal aggregation occurring at the centreline apex where the
predicted z-displacement was highest (Fig. 8e and f).
Discussion
Published findings from our laboratories and others demon-
strate that initial platelet aggregation at both in vivo and
in vitro stenosis geometries is initiated by local shear rate gradi-
ents and elevated wsr.31–33 Based on these findings we
hypothesised that micro-valve geometry with its impact on the
local haemodynamic environment is a key factor contributing
to microvalve haemocompatibility. Investigation of platelet sur-
face aggregation and bulk flow activation following blood per-
fusion through straight and v-gate valve iterations demon-
strated that v-shaped valves display less overall platelet
activation and aggregation than straight valve architectures.
We demonstrate that for either design, the degree of Ca2+ flux,
α-granule secretion (P-selectin expression), integrin αIIbβ3 acti-
vation, PS exposure, and platelet aggregation are affected by
the overall valve geometry. The consistent impact of valve ge-
ometry on a range of distinct platelet functional outputs sug-
gests that valve geometry needs to be carefully considered with
respect to downstream assay requirements, particularly where
specific aspects of platelet function are under investigation.
Confocal imaging following 5 min of blood perfusion
demonstrated that gate fouling was the result of consolidated
platelet aggregate formation extending both up and down-
stream of gate surfaces (Video S3†). The propensity of valve
gates to undergo fouling appeared to be initiated by, and
highly dependent on, the rapid formation of discrete “platelet
jets”. (Video S3†). Imaging of early stage platelet aggregation
at valve gate surfaces demonstrated that fouling initiated at
the upstream margins of the gates where acceleration in
shear rates were predicted. These observations correlate with
previously published observations from our laboratories that
have shown that microfluidic step geometries significantly
modulate platelet aggregation through the generation of
shear gradients that drive discoid platelet to platelet cohesion
events.33 The early stage “platelet jets” observed at valve gate
surfaces appear to be composed of strings of tethered plate-
lets reminiscent of observations made by our laboratories
and others that have demonstrated that at elevated shear
rates, or in the presence of significant shear rate gradients,
platelet recruitment is driven by discrete discoid platelet
membrane tethering, primarily driven by platelet GP1b/V/IX–
VWF binding events and the high shear unfolding and self-
association of VWF multimers.26,32,44 While it is not possible
to limit shear rate magnitude at operational gates due to flow
restriction during valve closure (under constant pressure con-
ditions), our current findings in conjunction with previously
published observations lead us to posit that further modifica-
tion of the overall shape of the upstream face of gate surfaces
(shallower entry angles), changes in the surface profile of the
bottom gate surface, and/or improved control of the rate of
gate closure and thereby modification of the overall shear
rate change, may further reduce or eliminate valve effects on
blood platelet function. Exploration of these design concepts,
while outside the scope of the current work, is under current
investigation.
Our CFD modelling suggests a significant shift in the
shear rate distribution across the v-gate surface in compari-
son to the straight valve case. Specifically, peak wsr was bi-
ased at the upstream edge of the v-gate apex; in contrast wsr
maxima were distributed relatively uniformly across the
straight gate surface. In addition our CFD modelling in con-
junction with our platelet flow and adhesion/aggregation
studies suggest that platelet path lines diverge across the
v-gate surface towards regions of overall lower wsr. Further-
more, our CFD modelling suggests that for the v-gate case
platelet trajectories may undergo displacement, away from
the gate surface, by up to 2.5× the average discoid platelet di-
ameter (3–8 μm from the gate surface) that may have the ad-
ditional effect of limiting platelet to v-gate surface interac-
tions during blood perfusion. This limitation on gate surface
contact may be a key determinant of the increased
haemocompatibility of the v-gate geometry as platelet aggre-
gate formation, and therefore fouling, is critically dependent
on the frequency and ability of platelets to interact with sur-
face immobilised adhesive substrates.
Surface passivation through chemical modification or pro-
tein blocking of PDMS based microfluidics has been the “go
to” method to limit blood dependent fouling. Physisorption
of serum albumin, Pluronic block copolymers, or more so-
phisticated PEGylation and silanization techniques have been
used to limit fouling,45,46 however the efficacy of these ap-
proaches is application specific.47,48 A key limitation of
physisorption based blocking techniques is the relatively la-
bile nature of these surface modifications limiting both de-
vice reliability and shelf life. Furthermore, while bulk protein
physisorption methods may limit some blood-surface interac-
tions in microfluidic systems, surface exchange of protein
species such as fibrinogen (the Vroman effect) is still possi-
ble, dependent on perfusion rates and exposure times.23 A
chief aim of the present study was therefore to identify a
microvalve design that minimises the requirements for sur-
face modification steps (pre-fouling) to achieve
haemocompatibility. Our experimental findings in combina-
tion with CFD modelling suggest that the haemodynamic
profile of valve surfaces may be a significant contributor to
both plasma protein adsorption and platelet surface interac-
tions. By controlling both valve gate haemodynamics and
therefore surface binding events it may be possible to de-
velop microfluidic blood-handling systems that do not re-
quire surface passivation, greatly simplifying the number of
device dependent steps and fabrication processes, and im-
proving device shelf life.
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Haematology based assays in the microfluidic context re-
quire a diverse range of flow rates dependent on assay re-
quirements ranging from rates as low as <1 μl min−1 to sev-
eral ml h−1.49–54 In the context of devices that require
complex switching control, rapid blood sample delivery and
flow rates have the potential to minimise sample handling
times and increase assay throughput. Relatively high flow
rates become increasingly important where relatively high
shear rates are required for test development, such as platelet
functional assays.55 In combination with our previously pub-
lished findings, our data support the concept that upstream
microvalved blood handling systems be designed in such a
way that they minimise both the overall applied shear rate (at
a given flow rate), but also seek to eliminate acute changes in
shear rate within valved components.31 We posit that this
may be of particular relevance during microvalve actuation,
where dynamically changing valve-gate geometry and there-
fore haemodynamic profile may significantly impact blood
function. In particular, the haemodynamic profile of valve
gates under conditions of partial actuation or during
opening-closing cycles where gates may transiently project
into blood flow is a key consideration. The ability of valve
gates to completely clear the microfluidic channel in the fully
open state is particularly critical, given our findings that
microvalves below a size cut-off of 400 μm2 may obstruct up
to 55% of microchannel height, leading to significant effects
on the haemodynamic profile and platelet function,
irrespective of gate geometry. This concept is supported by
our findings that at a fixed clearance height of 40 μm, where
shear rate gradients are acute, all valve types were found to
elicit increased levels of platelet aggregation and activation.
Critically, valves in the size range from 300–500 μm at a par-
tial opening height of 40 μm experienced complete occlusion
over a 200 s time frame, demonstrating that dynamic
changes in valve haemodynamics may play a critical role in
microfluidic fouling. This may be compounded by the duty
cycle of valve opening with repeated closure leading to in-
creased blood sample modification due to the repeated appli-
cation of transiently high shear rates.
Erythrocytes (RBC) may be damaged during flow in non-
physiological environments and under extreme shear stress,
such as that generated within microfluidic systems. Shear-
induced damage of RBC may result in haemolysis, echinocyte
formation (morphology change), or in altered mechanical
properties of RBC that in turn reduce their ability to with-
stand further damage by shear stress.56,57 Significantly, sub-
threshold shear stress that is applied over multiple cycles has
been shown to have a cumulative effect on RBC mechanical
stability.58 RBC mechanical stability (haemolysis) and mor-
phology (echinocyte formation) were significantly impacted
by valve size and geometry at a duty cycle of 1 Hz. Signifi-
cantly, v-shaped valves across the tested size range showed
no RBC haemolysis above no-valve controls, while for straight
valve designs haemolysis correlated inversely with valve size
at a duty cycle of 1 Hz. The echinocyte data suggest that RBC
deformability and membrane elasticity are significantly
influenced by valve geometry. Decrease in RBC deformability,
changes of cell volume, increased cellular rigidity, increased
levels of haemolysis, and changes in plasma membrane
structure, such as phosphatidyl serine exposure correlate
with increases in RBC [Ca2+]c.
43,59 Both RBC [Ca2+]c and PS ex-
posure showed a generalised inverse trend with respect to
valve size and geometry. The marginal increase in PS, while
not statistically significant, may be problematic where blood
coagulant function (contact activation) is a consideration,
particularly under conditions where blood samples have not
been adequately anti-coagulated. Our findings suggest that a
v-shaped valve design is superior as a single pass device, with
respect to RBC handling, but may also represent a suitable
design for serial valve systems, such as micropumps, where
RBC's may experience repeated exposure to elevated shear
rates.
A key limitation of this study is the use of an idealised
CFD model to describe a complex elastomeric microvalve sys-
tem and dynamic blood flow effects. The CFD mesh was de-
rived from confocal imaging of operational valves (free of
platelet aggregates) in both the partially and fully open
(static) states and CFD then carried out on these fixed states.
However, it should be noted that this CFD modelling ap-
proach is limited by the overall resolution limits of the confo-
cal system and does not account for transient or dynamic de-
formations of the elastomeric valves during actuation.
Furthermore, the CFD modelling carried out in this study
does not consider dynamic changes in valve geometry as a re-
sult of platelet binding and aggregation events. It is undoubt-
edly the case that platelet aggregation will feedback on local
haemodynamics and modify both peak shear rates and shear
rate gradients that are imposed on blood flow. These limita-
tions highlight the critical need for more complex and dy-
namic non-Newtonian and mechanical CFD models to more
accurately inform blood handling microfluidic development
in the future. Our interpretation of the overall
haemodynamics of valve iterations and the effects on blood
interactions therefore need to be qualified with these limita-
tions in mind. Secondly, while we have endeavoured to incor-
porate a battery of blood based functional assessments to
characterise valve performance these assays by no means ad-
dress all of the complex blood functions that may be impor-
tant for haemocompatibility. In this context, functional out-
puts to a large degree need to take into consideration the
flow rate requirements of the specific downstream assay in
use. Indeed, the flow rate range utilised across the blood
based microfluidic literature demonstrates the diversity in
possible assay conditions. Therefore the limitations of the
present study need to be considered in this broader context.
Conclusion
In conclusion, we demonstrate a hierarchy of elastomeric
microvalve design that demonstrates that v-shaped valves dis-
play the highest degree of haemocompatibility. Significantly,
this valve geometry minimises the requirements for surface
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chemical modification to reduce biofouling. Taken together
with previously published studies examining the impact of
shear rate and shear rate gradients on platelet and blood
function, this study highlights the importance of considering
the overall haemodynamic profile of microfluidic compo-
nents when designing blood-handling systems. We believe
that the approach defined in this study is a step toward ratio-
nal, biologically focused, blood handling microfluidic design,
with the potential to be extended to a range of microfluidic
components.
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CHAPTER 5: Conclusions and Future Work  
    
At the beginning of this thesis it was noted that while complex microfluidics were introduced 
several decades ago, and have been shown to enable significant outcomes in a research context, 
they have not yet achieved significant traction in real world end-user applications, and certainly 
have not seen the predicted disruptive impact analogous to introduction of the integrated circuit 
to the electronics industry, as anticipated in their early days. This thesis thus set out to explore the 
hypothesis that a key factor preventing the uptake and rapid development of complex 
microfluidics was the challenges associated with existing multilayer elastomer fabrication 
approaches. It was proposed that if a simplified approach could be developed, then this would 
lower the barrier to harnessing and developing this technology, and this would in turn accelerate 
it towards deployment in real world end-user applications. It was hoped that these steps might 
perhaps ultimately lead to the realisation of the full potential that complex multilayer microfluidic 
systems have been predicted to achieve.  
To this end, this thesis investigated a new fabrication method intended to facilitate practical 
realisation of complex multilayer microfluidic structures. Application of this fabrication method 
was explored in the context of real-world problems, assessing the practicality, adaptability and 
scalability of the method. Finally, the method was used to fabricate complex multilayer 
microfluidic systems in volumes required to enable biological studies, facilitating insights into the 
use of common multilayer control components for handling complex biological samples, studies 
that would be impractical with traditional methods.   
 
5.1 Outcomes of this work 
A primary outcome of this work was a fabrication method, outlined in chapter 2, which 
demonstrated that fabrication of key complex multilayer microfluidic components can be greatly 
simplified, overcoming numerous challenges associated with traditional multilayer fabrication 
methods. The level of simplification offered by this fabrication method was shown to allow 
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relatively simple and reliable fabrication of these common components, significantly reducing 
fabrication overheads. This method was demonstrated in a proof of concept capacity to allow the 
fluidic manipulation and environmental control sophistication advantages that complex multilayer 
microfluidic structures provide, with a level of accessibility similar to that available to basic 
microfluidic systems.  
Chapter 3 explored the practicalities of application for this technique, field testing the fabrication 
method in the context of real-world applications, but in the context of short-term collaborative 
engagements with researchers who could benefit from complex multilayer microfluidics, but who 
were not experts in the field. The adaptability of the fabrication method was explored, 
demonstrating its capacity to rapidly develop a toolbox of modular components, and adapt and 
refine these components and systems based on these components to create solutions to problems 
faced by the collaborating research teams. The collaborative projects focussed on integration of 
microfluidics with highly sensitive photonic biosensor platforms. In the first case study pneumatic 
microvalve based systems were adapted to perform assay automation and were integrated with a 
highly sensitive photonic biosensor platform, with the ultimate goal of creating a ‘point of care’ 
environmental detection of an antibiotic in seawater. In the second case study the new fabrication 
technique and toolbox of proven components was applied to enable sophisticated environmental 
control, adapting vapour permeable membranes and microvalve control elements to allow 
sophisticated environmental control of an isolated volume over an integrated plasmonic 
biosensor, facilitating long duration single cell analysis. Chapter 3 demonstrated that removing the 
fabrication bottleneck generally associated with complex multilayer microfluidic systems, enabled 
rapid development of practical solutions that genuinely improved the target applications at a 
speed that was feasible during short term and even remote collaboration.  Such rapid development 
and iterative improvement would have been impractical with traditional multi-layer fabrication 
methods. Overall, chapter 3 showed that the fabrication method introduced in chapter 2 showed 
significant potential for rapid development of research prototypes and was highly suitable for 
rapidly achieving significant outcomes through collaboration with researchers outside the field of 
microfluidics creating clear opportunities for growth in uptake of this technology.  
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Having shown in chapter 3 that fabrication technique of chapter 2 was very well suited to research 
collaboration, chapter 4 explored application of this approach in a biomedical clinical context 
investigation the utility of the platform when using whole blood and the scalability of the approach 
to producing 100’s of replicate devices needed for limited clinical trials.  The capacity of this 
fabrication method to handle increasingly complex biological samples was assessed, moving from 
blood plasma to whole blood. Chapter 4 established the hemocompatibility of the fabricated 
devices and a selection of modular building blocks demonstrating that microfluidic control 
functionality without significant deleterious impact on blood at physiologically relevant flow rates. 
The fabrication technique could enable practical fabrication of hundreds of replicate devices, 
enabling biological studies using complex multilayer microfluidic devices, that would otherwise be 
prohibitively difficult due to the large numbers of replicate devices required to gather statistically 
significant data. Overall, the chapter highlighted that platforms fabricated with the technique, 
were well suited to handling complex biological fluids, and this was validated in the context of a 
comprehensive battery of blood function assays. This initial research has attracted the attention 
of clinical researchers and even some initial interest from a point of care device company, 
indicating that the barrier to real world uptake of this technology in a clinical context has certainly 
been lowered.    
 
5.2 Concluding remarks and suggestions for future work 
The work in this thesis operates on the assumption that challenges associated with fabrication of 
complex multilayer microfluidic systems are a primary bottleneck preventing widespread 
acceptance of the technology. The work in this thesis has demonstrated that access to complex 
multilayer microfluidic systems without the fabrication overheads generally associated with these 
systems does allow their application to areas that would otherwise be prohibitively difficult. While 
overcoming fabrication challenges may allow the advantages of complex multilayer microfluidic 
systems to be applied to otherwise unexplored applications, there are of course other caveats 
associated with application of complex multilayer microfluidic systems.  
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During this work, there was significant interest in systems that can be realised through application 
of the fabrication technique, a fair amount of draw was generated, with numerous research 
avenues necessitating careful consideration of the direction of this research. It quickly became 
apparent that while design and fabrication of prototype systems has a short turnaround, 
deployment of these systems to additional real-world applications, is somewhat limited by the 
availability of support equipment. Each independently controllable on-chip microvalve component 
in this thesis required an off-chip electronically controlled solenoid valve and substantial additional 
external support equipment. While the work in this thesis chose not to focus on challenges 
associated with external support equipment or control interface, it is possible that another 
significant challenge in widespread acceptance of complex multilayer microfluidic systems is this 
complexity of control interface and required support equipment. This is particularly relevant in the 
case of pneumatic on chip control components, as these systems generally require elaborate 
pressure regulation subsystems and off-chip solenoid valve manifolds to actuate on-chip 
components. Simplified interfaces and robust, cheap support equipment are a critical requisite to 
successful point of care translation of complex multilayer microfluidic control components. As with 
other researchers in this field, it was possible to reduce this burden through parallelism using one 
external valve to control multiple on-chip valves in unison, however truly complex systems (with 
100’s or even 1000’s of valves) remain impractical due to the linear relationship between the on-
chip complexity and the interfaces and external support equipment required. 
A solution to this problem potentially exists in the direction of further integration. If it is possible 
to integrate some of the functionality of the external support equipment directly on-chip, it may 
be possible to scale on-chip complexity with a nonlinear reliance on interfaces and external 
systems. An initial implementation of this idea would be to move the electronically controlled 
solenoid valves on-chip, or to a semi integrated chip carrier component. While this would reduce 
the complexity of the external support equipment, the complexity of these integrated valves 
would again scale along with their application, and fabrication overheads would quite possibly 
outweigh any advantage. Another potential solution, which has attracted significant interest in the 
literature, would be implementation of an electronically addressed microvalve [54-56]. If it were 
possible to offload microvalve control interfaces to well established electronic systems, the issue 
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of interface would be significantly simplified, and external support equipment could be reduced 
to the scale of a simple microcontroller. It is possible that practical realisation of electronically 
addressable microvalves carries the promise of realising the predicted revolution in microfluidic 
system complexity, however, while promising, numerous challenges need to be overcome to 
enable practical realisation of electronically addressable microvalves. Such valves would require 
an actuation mechanism that can provide pressure differentials and scalability comparable with 
pneumatic or hydraulically driven microvalves, while the requirement for mechanical transducers 
generally introduce additional fabrication challenges and the scaling relationships for the energy 
required to switch valves may not favour miniaturisation. 
Alternatively, simplification of required external support equipment could potentially be achieved 
through increasing sophistication of on-chip systems, working toward serial control interfaces. As 
the computer industry moved from parallel communications interfaces, toward universal serial 
bus communications, a similar paradigm shift in on-chip pneumatic control components would 
drastically increase the available sophistication for a given level of off-chip complexity.  
Numerous advances have been made toward multiplexing and addressing regimes that enhance 
on-chip complexity while minimising required external control components. The field of 
microfluidic logic has demonstrated significant promise in this area, with various control 
components shown to duplicate the functionality of their electronic counterparts [17]. These 
systems have been shown to drastically reduce required control interfaces, with complex 
addressing schemes such as fluidic shift registers, allowing a degree of serial device interface. 
While these systems have achieved this outcome using various pathways, they generally share the 
common problem of exceedingly complex fabrication methods. This suggests a clear pathway for 
future research. If it is possible to fabricate these systems without their significant fabrication 
overheads, it may be possible to realise the full potential of complex multilayer microfluidic 
systems. This could make commonplace the kind of exponentially complex on-chip systems, with 
minimised interfaces, as was a primary factor in advancing the electronics industry. 
Future work is planned to explore application of the simplified fabrication techniques outlined in 
this thesis, to practically realise microfluidic logic circuitry. While microfluidic logic systems are 
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generally fabricated with fairly complex fabrication methods, it should be possible to realise most 
of the required geometries with the technique, with one key exception. Reliable formation of 
viaduct pathways between top and bottom layer features remains a challenge with the PDMS 
injection moulding fabrication technique. There are various pathways that can be taken toward 
including reliable viaduct fabrication in the list of multilayer components that can be included in 
devices fabricated with this technique, and as further work beyond the scope of this thesis, I would 
suggest this as a vital component enabling the next step toward simplified integration of complex 
microfluidic logic circuitry. 
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